



Clinical trial results:

Lean Efficacy Phase IIa Proof of concept trial (LEAAP). A multi-centre, double-blind, placebo controlled, randomised study in overweight and obese patients during twenty-six weeks, investigating the effect of EMP16-02 on body weight, safety and clinical biomarkers

Summary

EudraCT number	2019-004545-32
Trial protocol	SE
Global end of trial date	30 August 2021

Results information

Result version number	v1 (current)
This version publication date	08 September 2022
First version publication date	08 September 2022

Trial information

Trial identification

Sponsor protocol code	EP-002
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Empros Pharma AB
Sponsor organisation address	Nanna Svartz väg 4, Solna, Sweden, SE-171 65
Public contact	Arvid Söderhäll, Empros Pharma AB, +46 707233363, arvid.soderhall@emprospharma.com
Scientific contact	Arvid Söderhäll, Empros Pharma AB, +46 707233363, arvid.soderhall@emprospharma.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	30 August 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	30 August 2021
Global end of trial reached?	Yes
Global end of trial date	30 August 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the effect of the study drug EMP16-02 (120 mg orlistat [O]/40 mg acarbose [A]) on relative body weight loss after a 26-week period of oral treatment as compared to placebo.

Protection of trial subjects:

The ICFs included information that the data that were recorded, collected and processed could be transferred to the European Economic Area (EEA) or non-EEA countries. In accordance with the General Data protection Regulation (GDPR) (EU) 2016/679, the data did not allow for identification of any persons taking part in the study.

The potential study patient was informed that by signing the ICF he/she approved that authorized representatives from the Sponsor and CTC, the concerned Ethical Committee (EC) and CA had direct access to his/her medical records for verification of clinical study procedures. This agreement was substantiated in a separate document, according to local requirements.

The patient had the right to request access to his/her personal data and the right to request rectification of any data that were not correct and/or complete.

The Investigator had to file a Patient Identification List which included sufficient information to link records, i.e. the eCRF and clinical records. This list will be preserved for possible future inspections/audits but will not be made available to the Sponsor except for monitoring or auditing purposes.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	07 May 2020
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy, Scientific research
Long term follow-up duration	6 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Sweden: 156
Worldwide total number of subjects	156
EEA total number of subjects	156

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	135
From 65 to 84 years	21
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The subjects were recruited from CTC's database of healthy volunteers and patients, and from advertising in media (including social media).

Pre-assignment

Screening details:

A total of 209 patients were screened and 156 were randomized (52 patients per treatment group). Thirty-seven patients were screening failures, 6 withdrew consent prior to randomization and 10 were not randomized due to other reasons (fulfilled eligibility criteria but were not needed in the study).

Period 1

Period 1 title	Main study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst

Blinding implementation details:

This was a double-blind study, and the allocation of treatments was not disclosed until clean file had been declared and the database had been locked. Active treatment and placebo capsules were identical in appearance.

Arms

Are arms mutually exclusive?	Yes
Arm title	EMP16-02 - 120/40

Arm description:

In this study patients were randomized in a 1:1:1 ratio to either of 2 doses of EMP16-02 or placebo. This arm (n=52) represents the group of patients who were randomized to receive EMP16-02 -120/40 (120 mg orlistat/40 mg acarbose).

Arm type	Experimental
Investigational medicinal product name	EMP16-02
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

The drug product, EMP16-02, is a fixed dose combination (FDC) that contains 2 active pharmaceutical ingredients (APIs), namely orlistat (O) and acarbose (A). The IMP was supplied as oral modified release (MR) capsules in 2 different strengths: 60 mg O/20 mg A and 90 mg O/30 mg A. The dose used in this treatment arm was 120 mg O/40 mg A (2 capsules EMP16-02-60/20).

The IMP was to be taken halfway into a meal 3 times daily (TID) with approximately 100-200 mL water or other drink. The IMP was not to be taken on an empty stomach. The patients were recommended to leave 3-4 h between each meal/IMP dose.

The patients started with a titration period of 6 weeks during which the dose was sequentially increased in order to let patients gradually adapt to the acarbose dose. The IMP was administered TID also during the titration period. At week 7, all patients had reached their final intended dose and a 20-week treatment and observation period started.

Arm title	EMP16-02 - 150/50
------------------	-------------------

Arm description:

In this study patients were randomized in a 1:1:1 ratio to either of 2 doses of EMP16-02 or placebo. This arm (n=52) represents the group of patients who were randomized to receive EMP16-02-150/50 (150 mg orlistat/50 mg acarbose).

Arm type	Experimental
----------	--------------

Investigational medicinal product name	EMP16-02
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

The drug product, EMP16-02, is a fixed dose combination (FDC) that contains 2 active pharmaceutical ingredients (APIs), namely orlistat (O) and acarbose (A). The IMP was supplied as oral modified release (MR) capsules in 2 different strengths: 60 mg O/20 mg A and 90 mg O/30 mg A. The dose used in this treatment arm was 150 mg O/50 mg A (1 capsule EMP16-02-90/30 and 1 capsule EMP16-02-60/20).

The IMP was to be taken halfway into a meal 3 times daily (TID) with approximately 100-200 mL water or other drink. The IMP was not to be taken on an empty stomach. The patients were recommended to leave 3-4 h between each meal/IMP dose.

The patients started with a titration period of 6 weeks during which the dose was sequentially increased in order to let patients gradually adapt to the acarbose dose. The IMP was administered TID also during the titration period. At week 7, all patients had reached their final intended dose and a 20-week treatment and observation period started.

Arm title	Placebo
------------------	---------

Arm description:

In this study patients were randomized in a 1:1:1 ratio to either of 2 doses of EMP16-02 or placebo. This arm (n=52) represents the group of patients who were randomized to receive placebo.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Placebo was a matching, oral capsule containing only cellulose.

The IMP was to be taken halfway into a meal 3 times daily (TID) for 26 weeks, together with approximately 100-200 mL water or other drink. The IMP was not to be taken on an empty stomach. The patients were recommended to leave 3-4 h between each meal/IMP dose.

Number of subjects in period 1	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo
Started	52	52	52
Completed	44	45	46
Not completed	8	7	6
Consent withdrawn by subject	3	2	5
Adverse event, non-fatal	4	5	-
Lost to follow-up	1	-	-
Protocol deviation	-	-	1

Baseline characteristics

Reporting groups

Reporting group title	EMP16-02 - 120/40
Reporting group description:	
In this study patients were randomized in a 1:1:1 ratio to either of 2 doses of EMP16-02 or placebo. This arm (n=52) represents the group of patients who were randomized to receive EMP16-02 -120/40 (120 mg orlistat/40 mg acarbose).	
Reporting group title	EMP16-02 - 150/50
Reporting group description:	
In this study patients were randomized in a 1:1:1 ratio to either of 2 doses of EMP16-02 or placebo. This arm (n=52) represents the group of patients who were randomized to receive EMP16-02-150/50 (150 mg orlistat/50 mg acarbose).	
Reporting group title	Placebo
Reporting group description:	
In this study patients were randomized in a 1:1:1 ratio to either of 2 doses of EMP16-02 or placebo. This arm (n=52) represents the group of patients who were randomized to receive placebo.	

Reporting group values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo
Number of subjects	52	52	52
Age categorical Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			
Adults (18-64 years)			
From 65-84 years			
85 years and over			
Age continuous Units: years			
arithmetic mean	49.4	50.7	49.5
standard deviation	± 12.2	± 13.6	± 12.8
Gender categorical Units: Subjects			
Female	38	36	37
Male	14	16	15
Body Mass Index (BMI) Units: (kg/m2)			
arithmetic mean	35.1	34.6	36.2
standard deviation	± 3.3	± 3.6	± 4.5

Reporting group values	Total		
Number of subjects	156		
Age categorical Units: Subjects			
In utero	0		

Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	0		
From 65-84 years	0		
85 years and over	0		
Age continuous Units: years arithmetic mean standard deviation	-		
Gender categorical Units: Subjects			
Female	111		
Male	45		
Body Mass Index (BMI) Units: (kg/m2) arithmetic mean standard deviation	-		

End points

End points reporting groups

Reporting group title	EMP16-02 - 120/40
Reporting group description: In this study patients were randomized in a 1:1:1 ratio to either of 2 doses of EMP16-02 or placebo. This arm (n=52) represents the group of patients who were randomized to receive EMP16-02 -120/40 (120 mg orlistat/40 mg acarbose).	
Reporting group title	EMP16-02 - 150/50
Reporting group description: In this study patients were randomized in a 1:1:1 ratio to either of 2 doses of EMP16-02 or placebo. This arm (n=52) represents the group of patients who were randomized to receive EMP16-02-150/50 (150 mg orlistat/50 mg acarbose).	
Reporting group title	Placebo
Reporting group description: In this study patients were randomized in a 1:1:1 ratio to either of 2 doses of EMP16-02 or placebo. This arm (n=52) represents the group of patients who were randomized to receive placebo.	

Primary: Relative (%) change from baseline in body weight after 26 weeks

End point title	Relative (%) change from baseline in body weight after 26 weeks
End point description: Weight was measured in kg (one decimal) without shoes and without thick clothes such as jumpers at pre-specified visits. This end-point reports the mean relative (%) change from baseline (Visit 2, pre-dose) in body weight at Week 26. The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.	
End point type	Primary
End point timeframe: Weight was assessed at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	45	46	
Units: percent				
arithmetic mean (standard deviation)				
Visit 5 (week 26), pre-dose	-5.8 (± 5.3)	-6.5 (± 4.4)	-0.7 (± 3.7)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
Statistical analysis description: Relative (%) change from baseline in body weight after 26 weeks of treatment with EMP16-02 (120 mg O/40 mg A) as compared to placebo was analysed using analysis of variance with treatment as the	

independent variable. Hypothesis testing was two-sided. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[1]
Method	ANOVA

Notes:

[1] - Hypothesis testing used a 5% significance level ($\alpha=0.05$).

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

Relative (%) change from baseline in body weight after 26 weeks of treatment with EMP16-02 (150 mg O/50 mg A) as compared to placebo was analysed using analysis of variance with treatment as the independent variable. Hypothesis testing was two-sided. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	91
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANOVA

Secondary: Absolute change from baseline in body weight after 14 and 26 weeks

End point title	Absolute change from baseline in body weight after 14 and 26 weeks
-----------------	--

End point description:

Weight was measured in kg (one decimal) without shoes and without thick clothes such as jumpers at pre-specified visits. This end-point reports the mean absolute change from baseline (Visit 2, pre-dose) in body weight at Week 14 and Week 26.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Weight was assessed at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45 ^[2]	47 ^[3]	49 ^[4]	
Units: kg				
arithmetic mean (standard deviation)				
Visit 4 (week 14), pre-dose	-4.29 (\pm 3.19)	-4.83 (\pm 3.11)	-1.18 (\pm 3.30)	
Visit 5 (week 26), pre-dose	-5.75 (\pm 5.35)	-6.44 (\pm 4.59)	-0.78 (\pm 3.75)	

Notes:

[2] - n=45 for Visit 4 and n=44 for Visit 5

[3] - n=47 for visit 4 and n=45 for Visit 5

[4] - n=49 for Visit 4 and n=46 for Visit 5

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14 & Week 26
-----------------------------------	--

Statistical analysis description:

Absolute change from baseline in body weight was analysed using the ANCOVA model, with treatment as independent variable and weight at baseline as covariate. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 94 for Week 14 and 90 for Week 26.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[5]
Method	ANCOVA

Notes:

[5] - This p-value applies for both Week 14 and Week 26.

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14 & Week 26
-----------------------------------	--

Statistical analysis description:

Absolute change from baseline in body weight was analysed using the ANCOVA model, with treatment as independent variable and weight at baseline as covariate. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 96 for Week 14 and 91 for Week 26.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[6]
Method	ANCOVA

Notes:

[6] - This p-value applies for both Week 14 and Week 26.

Secondary: Relative (%) change from baseline in body weight after 14 weeks

End point title	Relative (%) change from baseline in body weight after 14 weeks
-----------------	---

End point description:

Weight was measured in kg (one decimal) without shoes and without thick clothes such as jumpers at pre-specified visits. This end-point reports the mean relative (%) change from baseline (Visit 2, pre-dose) at Week 14.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Weight was assessed at Visit 2 (Day 1, baseline), Visit 3 (Week 7) and Visit 4 (Week 14).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	47	49	
Units: percent				
arithmetic mean (standard deviation)				
Visit 4 (Week 14), pre-dose	-4.4 (\pm 3.1)	-4.8 (\pm 2.9)	-1.1 (\pm 3.1)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
----------------------------	--

Statistical analysis description:

Relative (%) change from baseline in body weight after 14 weeks of treatment with EMP16-02 (120 mg O/40 mg A) as compared to placebo was analysed using analysis of variance with treatment as the independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	Placebo v EMP16-02 - 120/40
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
----------------------------	--

Statistical analysis description:

Relative (%) change from baseline in body weight after 14 weeks of treatment with EMP16-02 (150 mg O/50 mg A) as compared to placebo was analysed using analysis of variance with treatment as the independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANOVA

Secondary: Proportion of patients with $\geq 5\%$ and $\geq 10\%$ decrease in body weight compared to baseline after 14 weeks

End point title	Proportion of patients with $\geq 5\%$ and $\geq 10\%$ decrease in body weight compared to baseline after 14 weeks
-----------------	--

End point description:

Weight was measured in kg (one decimal) without shoes and without thick clothes such as jumpers at pre-specified visits. This end-point reports the proportions (%) of patients with $\geq 5\%$ and $\geq 10\%$

decrease in body weight relative to baseline (Visit 2, pre-dose) at Week 14.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
End point timeframe:	
Weight was assessed at Visit 2 (Day 1, baseline), Visit 3 (Week 7) and Visit 4 (Week 14).	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	47	49	
Units: percent				
number (not applicable)				
≥5% decrease - Visit 4 (week 14), pre-dose	31	43	14	
≥10% decrease - Visit 4 (week 14), pre-dose	8.9	4.3	0	

Statistical analyses

Statistical analysis title	EMP16-02-120/40 VS placebo - ≥5% decrease -Week 14
Statistical analysis description:	
The proportion of patients with ≥5% decrease in body weight compared to baseline after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using chi-square test without continuity correction.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0504
Method	Chi-squared

Statistical analysis title	EMP16-02-150/50 VS placebo - ≥5% decrease -Week 14
Statistical analysis description:	
The proportion of patients with ≥5% decrease in body weight compared to baseline after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using chi-square test without continuity correction.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0021
Method	Chi-squared

Statistical analysis title	EMP16-02-120/40 VS placebo- $\geq 10\%$ decrease -Week 14
Statistical analysis description: The proportion of patients with $\geq 10\%$ decrease in body weight compared to baseline after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using chi-square test without continuity correction.	
Comparison groups	Placebo v EMP16-02 - 120/40
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0329
Method	Chi-squared

Statistical analysis title	EMP16-02-150/50 VS placebo- $\geq 10\%$ decrease -Week 14
Statistical analysis description: The proportion of patients with $\geq 10\%$ decrease in body weight compared to baseline after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using chi-square test without continuity correction.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1445
Method	Chi-squared

Secondary: Proportion of patients with $\geq 5\%$ and $\geq 10\%$ decrease in body weight compared to baseline after 26 weeks

End point title	Proportion of patients with $\geq 5\%$ and $\geq 10\%$ decrease in body weight compared to baseline after 26 weeks
-----------------	--

End point description:

Weight was measured in kg (one decimal) without shoes and without thick clothes such as jumpers at pre-specified visits. This end-point reports the proportions (%) of patients with $\geq 5\%$ and $\geq 10\%$ decrease in body weight relative to baseline (Visit 2, pre-dose) at Week 26.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Weight was assessed at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	45	46	
Units: percent				
number (not applicable)				
≥5% decrease - Visit 5 (week 26), pre-dose	55	67	13	
≥10% decrease - Visit 5 (week 26), pre-dose	23	22	2.2	

Statistical analyses

Statistical analysis title	EMP16-02-120/40 VS placebo - ≥5% decrease -Week 26
Statistical analysis description: The proportion of patients with ≥5% decrease in body weight compared to baseline after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using chi-square test without continuity correction.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Chi-squared

Statistical analysis title	EMP16-02-150/50 VS placebo - ≥5% decrease -Week 26
Statistical analysis description: The proportion of patients with ≥5% decrease in body weight compared to baseline after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using chi-square test without continuity correction.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	91
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Chi-squared

Statistical analysis title	EMP16-02-120/40 VS placebo- ≥10% decrease -Week 26
Statistical analysis description: The proportion of patients with ≥10% decrease in body weight compared to baseline after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using chi-square test without continuity correction.	
Comparison groups	EMP16-02 - 120/40 v Placebo

Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0029
Method	Chi-squared

Statistical analysis title	EMP16-02-150/50 VS placebo- $\geq 10\%$ decrease -Week 26
-----------------------------------	---

Statistical analysis description:

The proportion of patients with $\geq 10\%$ decrease in body weight compared to baseline after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using chi-square test without continuity correction.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	91
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0034
Method	Chi-squared

Secondary: Relative (%) change from baseline in BMI after 14 and 26 weeks

End point title	Relative (%) change from baseline in BMI after 14 and 26 weeks
-----------------	--

End point description:

Weight was measured in kg (one decimal) without shoes and without thick clothes such as jumpers at pre-specified visits. Height was measured in cm (no decimals) without shoes at screening (Visit 1). BMI was calculated based on the height measured at Visit 1 and the weight measured at each visit analyzed.

This end-point reports the mean relative (%) change in BMI from baseline (Visit 2, pre-dose) at Week 14 and Week 26.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Weight was assessed at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26). Height was measured at Visit 1 Screening.

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45 ^[7]	47 ^[8]	49 ^[9]	
Units: percent				
arithmetic mean (standard deviation)				
Visit 4 (week 14), pre-dose	-4.4 (\pm 3.1)	-4.8 (\pm 3.0)	-1.0 (\pm 3.1)	
Visit 5 (Week 26), pre-dose	-5.8 (\pm 5.3)	-6.5 (\pm 4.4)	-0.7 (\pm 3.7)	

Notes:

[7] - n=45 for Visit 4 and n=44 for Visit 5

[8] - n=47 for Visit 4 and n=45 for Visit 5

[9] - n=49 for Visit 4 and n=46 for Visit 5

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14 & Week 26
-----------------------------------	--

Statistical analysis description:

The relative change from baseline in BMI after 14 and 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 94 and 90 for weeks 14 and 26 respectively.

Comparison groups	Placebo v EMP16-02 - 120/40
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[10]
Method	ANOVA

Notes:

[10] - This p-value applies to both Week 14 and Week 26.

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14 & Week 26
-----------------------------------	--

Statistical analysis description:

The relative change from baseline in BMI after 14 and 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 96 and 91 for weeks 14 and 26 respectively.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[11]
Method	ANOVA

Notes:

[11] - This p-value applies to both Week 14 and Week 26.

Secondary: Absolute change from baseline in BMI after 14 and 26 weeks

End point title	Absolute change from baseline in BMI after 14 and 26 weeks
------------------------	--

End point description:

Weight was measured in kg (one decimal) without shoes and without thick clothes such as jumpers at pre-specified visits. Height was measured in cm (no decimals) without shoes at screening (Visit 1). BMI was calculated based on the height measured at Visit 1 and the weight measured at each visit analyzed.

This end-point reports the mean absolute change in BMI from baseline (Visit 2, pre-dose) at Week 14 and Week 26.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
End point timeframe:	
Weight was assessed at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26). Height was measured at Visit 1 Screening.	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45 ^[12]	47 ^[13]	49 ^[14]	
Units: kg/m2				
arithmetic mean (standard deviation)				
Visit 4 (week 14), pre-dose	-1.55 (± 1.18)	-1.67 (± 1.08)	-0.40 (± 1.17)	
Visit 5 (Week 26), pre-dose	-2.08 (± 1.99)	-2.23 (± 1.57)	-0.25 (± 1.33)	

Notes:

[12] - n=45 for Visit 4 and n=44 for Visit 5

[13] - n=47 for Visit 4 and n=45 for Visit 5

[14] - n=49 for Visit 4 and n=46 for Visit 5

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14 & 26
----------------------------	---

Statistical analysis description:

The absolute change from baseline in BMI after 14 and 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subject included in the analyses were 94 and 90 for Week 14 and Week 26 respectively.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[15]
Method	ANCOVA

Notes:

[15] - This p-value applies to both Week 14 and 26.

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14 & 26
----------------------------	---

Statistical analysis description:

The absolute change from baseline in BMI after 14 and 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subject included in the analyses were 96 and 91 for Week 14 and Week 26 respectively.

Comparison groups	Placebo v EMP16-02 - 150/50
-------------------	-----------------------------

Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[16]
Method	ANCOVA

Notes:

[16] - This p-value applies to both Week 14 and 26.

Secondary: Absolute change from baseline in waist circumference after 14 weeks

End point title	Absolute change from baseline in waist circumference after 14 weeks
-----------------	---

End point description:

Waist circumference was measured in cm (one decimal) at pre-specified visits. This end-point reports the mean absolute change from baseline (Visit 2, Day 1) in waist circumference at Week 14.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Waist circumference was assessed at Visit 2 (Day 1, baseline), Visit 3 (Week 7) and Visit 4 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	46	48	
Units: centimetre				
arithmetic mean (standard deviation)				
Visit 4 (week 14), pre-dose	-3.92 (± 6.02)	-3.83 (± 4.11)	-3.22 (± 4.67)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - week 14
----------------------------	--

Statistical analysis description:

The absolute change from baseline in waist circumference after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5054
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
----------------------------	--

Statistical analysis description:

The absolute change from baseline in waist circumference after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	Placebo v EMP16-02 - 150/50
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5552
Method	ANCOVA

Secondary: Absolute change from baseline in waist circumference after 26 weeks

End point title	Absolute change from baseline in waist circumference after 26 weeks
-----------------	---

End point description:

Waist circumference was measured in cm (one decimal) at pre-specified visits. This end-point reports the mean absolute change from baseline (Visit 2, Day 1) in waist circumference at Week 26.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Waist circumference was assessed at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26) .

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	44	45	
Units: centimetre				
arithmetic mean (standard deviation)				
Visit 5 (Week 26), pre-dose	-6.61 (± 5.67)	-6.80 (± 5.52)	-3.36 (± 5.36)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in waist circumference after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 120/40 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0087
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in waist circumference after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0047
Method	ANCOVA

Secondary: Absolute change from baseline in sagittal diameter after 14 weeks

End point title	Absolute change from baseline in sagittal diameter after 14 weeks
-----------------	---

End point description:

Sagittal diameter was measured in cm (one decimal) at pre-specified visits. For measurement of the sagittal diameter, the patient lied down on his/her back while having knees bent, so that the lower back was in contact with the surface he/she was lying on. The distance from the back to the highest point of the abdomen was measured in cm while the patient exhaled.

This end-point reports the mean absolute change from baseline (Visit 2, Day 1) in sagittal diameter at week 14.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Sagittal abdominal diameter was assessed at Visit 2 (Day 1) and Visit 4 (Week 14).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	47	49	
Units: centimetre				
arithmetic mean (standard deviation)				
Visit 4 (week 14), pre-dose	-1.79 (± 2.02)	-1.71 (± 2.16)	-0.75 (± 1.85)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
Statistical analysis description: The absolute change from baseline in sagittal diameter after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0075
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
Statistical analysis description: The absolute change from baseline in sagittal diameter after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0142
Method	ANCOVA

Secondary: Absolute change from baseline in sagittal diameter after 26 weeks

End point title	Absolute change from baseline in sagittal diameter after 26 weeks
-----------------	---

End point description:

Sagittal diameter was measured in cm (one decimal) at pre-specified visits. For measurement of the sagittal diameter, the patient lied down on his/her back while having knees bent, so that the lower back was in contact with the surface he/she was lying on. The distance from the back to the highest point of the abdomen was measured in cm while the patient exhaled.

This end-point reports the mean absolute change from baseline (Visit 2, Day 1) in sagittal diameter at Week 26.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Sagittal abdominal diameter was assessed at Visit 2 (Day 1), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	45	46	
Units: centimetre				
arithmetic mean (standard deviation)				
Visit 5 (Week 26), pre-dose	-1.35 (± 2.22)	-1.89 (± 2.06)	-0.49 (± 2.13)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
----------------------------	--

Statistical analysis description:

The absolute change from baseline in sagittal diameter after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0522
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
----------------------------	--

Statistical analysis description:

The absolute change from baseline in sagittal diameter after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	91
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.002
Method	ANCOVA

Secondary: Relative (%) change from baseline in percentage body fat after 14 weeks

End point title	Relative (%) change from baseline in percentage body fat after 14 weeks
-----------------	---

End point description:

Body composition (percentage body fat) was measured using a bio-impedance measuring device (Tanita BC-545N), according to the manufacturer's instructions, at pre-specified visits during the study.

This end-point reports the mean relative (%) change from baseline (Visit 2, Day 1) in percentage body fat after 14 weeks.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Percentage body fat was assessed at Visit 2 (Day 1) and Visit 4 (Week 14).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	47	49	
Units: percent				
arithmetic mean (standard deviation)				
Visit 4 (week 14), pre-dose	-0.4 (± 9.1)	-2.8 (± 6.2)	0.5 (± 5.8)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in percentage body fat after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3682
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in percentage body fat after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 150/50 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0233
Method	ANOVA

Secondary: Relative (%) change from baseline in percentage body fat after 26 weeks

End point title	Relative (%) change from baseline in percentage body fat after 26 weeks
-----------------	---

End point description:

Body composition (percentage body fat) was measured using a bio-impedance measuring device (Tanita BC-545N), according to the manufacturer's instructions, at pre-specified visits during the study.

This end-point reports the mean relative (%) change from baseline (Visit 2, Day 1) in percentage body fat after 26 weeks.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Percentage body fat was assessed at Visit 2 (Day 1) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	45	46	
Units: percent				
arithmetic mean (standard deviation)				
Visit 5 (Week 26), pre-dose	-2.8 (± 10.2)	-5.4 (± 7.4)	-0.3 (± 7.8)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
----------------------------	--

Statistical analysis description:

The relative (%) change from baseline in percentage body fat after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1733
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
Statistical analysis description: The relative (%) change from baseline in percentage body fat after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	91
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0047
Method	ANOVA

Secondary: Absolute change from baseline in percentage body fat after 14 weeks

End point title	Absolute change from baseline in percentage body fat after 14 weeks
-----------------	---

End point description:

Body composition (percentage body fat) was measured using a bio-impedance measuring device (Tanita BC-545N), according to the manufacturer's instructions, at pre-specified visits during the study.

This end-point reports the mean absolute change from baseline (Visit 2, Day 1) in percentage body fat after 14 weeks.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Percentage body fat was assessed at Visit 2 (Day 1) and Visit 4 (Week 14).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	47	49	
Units: percent				
arithmetic mean (standard deviation)				
Visit 4 (week 14), pre-dose	-0.40 (± 3.33)	-1.11 (± 2.24)	0.15 (± 2.40)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in percentage of body fat after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment and body weight at

baseline as covariates. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2727
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in percentage of body fat after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment and body weight at baseline as covariates. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0195
Method	ANCOVA

Secondary: Absolute change from baseline in percentage body fat after 26 weeks

End point title	Absolute change from baseline in percentage body fat after 26 weeks
-----------------	---

End point description:

Body composition (percentage body fat) was measured using a bio-impedance measuring device (Tanita BC-545N), according to the manufacturer's instructions, at pre-specified visits during the study.

This end-point reports the mean absolute change from baseline (Visit 2, Day 1) in percentage body fat after 26 weeks.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Percentage body fat was assessed at Visit 2 (Day 1) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	45	46	
Units: percent				
arithmetic mean (standard deviation)				
Visit 5 (Week 26), pre-dose	-1.45 (± 3.73)	-2.21 (± 2.68)	-0.19 (± 3.13)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
Statistical analysis description: The absolute change from baseline in percentage of body fat after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment and body weight at baseline as covariates. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0676
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
Statistical analysis description: The absolute change from baseline in percentage of body fat after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment and body weight at baseline as covariates. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	91
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0035
Method	ANCOVA

Secondary: Relative change from baseline in satiety and craving after 14 weeks

End point title	Relative change from baseline in satiety and craving after 14 weeks
End point description: The satiety and craving questionnaire consists of 7 questions about sense of hunger, sense of satiety and craving for certain types of food that need to be answered on a scale from 0 (not at all) to 9 (extremely much). At each applicable visit, the patients answered the questionnaire once prior to breakfast and 4 times after breakfast (once every hour). The total score of all questionnaires were combined in descriptive summaries. A low score indicates low appetite while a high score indicates high appetite. This end-point reports the mean relative (%) change from baseline (Visit 2, Day 1) in total score at week 14. The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.	
End point type	Secondary

End point timeframe:

The satiety and craving questionnaires were filled in by the patients at Visit 2 (Day1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26). The questionnaires were filled in before breakfast, then every hour for 4 hours until lunch.

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	38	37	35	
Units: percent				
arithmetic mean (standard deviation)				
Visit 4 (week 14)	3.2 (± 34.6)	1.5 (± 27.9)	-1.1 (± 34.1)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
Statistical analysis description:	
The Satiety and craving questionnaire includes 7 questions, with a scale 0 (not at all) to 9 (extremely much). The second and third question in the questionnaire were reversed before calculating the total score. Satiety and craving as total score after 14 weeks of treatment with EMP16-120/40 as compared to placebo, corrected for hunger and craving after standardised breakfast at baseline, was analyzed using the Wilcoxon Rank Sum test.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6389
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
Statistical analysis description:	
The Satiety and craving questionnaire includes 7 questions, with a scale 0 (not at all) to 9 (extremely much). The second and third question in the questionnaire were reversed before calculating the total score. Satiety and craving as total score after 14 weeks of treatment with EMP16-150/50 as compared to placebo, corrected for hunger and craving after standardised breakfast at baseline, was analyzed using the Wilcoxon Rank Sum test.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7017
Method	Wilcoxon (Mann-Whitney)

Secondary: Relative change from baseline in satiety and craving after 26 weeks

End point title	Relative change from baseline in satiety and craving after 26 weeks
End point description:	
<p>The satiety and craving questionnaire consists of 7 questions about sense of hunger, sense of satiety and craving for certain types of food that need to be answered on a scale from 0 (not at all) to 9 (extremely much). At each applicable visit, the patients answered the questionnaire once prior to breakfast and 4 times after breakfast (once every hour). The total score of all questionnaires were combined in descriptive summaries. A low score indicates low appetite while a high score indicates high appetite. This end-point reports the mean relative (%) change from baseline (Visit 2, Day 1) in total score at week 14.</p> <p>The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.</p>	
End point type	Secondary
End point timeframe:	
<p>The satiety and craving questionnaires were filled in by the patients at Visit 2 (Day1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26). The questionnaires were filled in before breakfast, then every hour for 4 hours until lunch.</p>	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	35	34	38	
Units: percent				
arithmetic mean (standard deviation)				
Visit 5 (Week 26)	12.7 (± 40.3)	3.6 (± 34.0)	3.3 (± 37.7)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
Statistical analysis description:	
<p>The Satiety and craving questionnaire includes 7 questions, with a scale 0 (not at all) to 9 (extremely much). The second and third question in the questionnaire were reversed before calculating the total score. Satiety and craving as total score after 26 weeks of treatment with EMP16-120/40 as compared to placebo, corrected for hunger and craving after standardised breakfast at baseline, was analyzed using the Wilcoxon Rank Sum test.</p>	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1762
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
Statistical analysis description:	
<p>The Satiety and craving questionnaire includes 7 questions, with a scale 0 (not at all) to 9 (extremely much). The second and third question in the questionnaire were reversed before calculating the total score. Satiety and craving as total score after 26 weeks of treatment with EMP16-150/50 as compared to placebo, corrected for hunger and craving after standardised breakfast at baseline, was analyzed</p>	

using the Wilcoxon Rank Sum test.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9057
Method	Wilcoxon (Mann-Whitney)

Secondary: Relative (%) change from baseline in fasting albumin after 7, 14 and 26 weeks

End point title	Relative (%) change from baseline in fasting albumin after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean relative (%) change from baseline in fasting albumin after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[17]	50 ^[18]	50 ^[19]	
Units: percent				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	1.4 (± 7.4)	1.9 (± 7.2)	-0.5 (± 6.3)	
VISIT 4 (WEEK 14), PREDOSE	-1.3 (± 4.5)	-2.2 (± 7.2)	-3.5 (± 5.3)	
VISIT 5 (WEEK 26), PREDOSE	-0.3 (± 5.8)	-0.4 (± 7.2)	-0.8 (± 6.0)	

Notes:

[17] - n=48 for week 7, n=45 for week 14 and n=44 for week 26

[18] - n=50 for week 7, n=47 for week 14 and n=45 for week 26

[19] - n=50 for week 7, n=49 for week 14 and n=46 for week 26

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
----------------------------	---------------------------------------

Statistical analysis description:

The relative (%) change from baseline in fasting albumin after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 120/40 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1787
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
-----------------------------------	---------------------------------------

Statistical analysis description:

The relative (%) change from baseline in fasting albumin after 7 weeks of treatment with or EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	Placebo v EMP16-02 - 150/50
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0897
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting albumin after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in this analysis was 94 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0447
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting albumin after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in this analysis was 96 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1122
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting albumin after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in this analysis was 90 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3186
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting albumin after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in this analysis was 91 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3509
Method	ANOVA

Secondary: Relative (%) change from baseline in fasting glucose after 7, 14 and 26 weeks

End point title	Relative (%) change from baseline in fasting glucose after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean relative (%) change from baseline in fasting glucose after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
End point timeframe:	
Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[20]	50 ^[21]	50 ^[22]	
Units: percent				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	-2.3 (± 7.2)	-2.5 (± 9.9)	-1.4 (± 6.2)	
VISIT 4 (WEEK 14), PREDOSE	-4.5 (± 7.9)	-4.2 (± 8.9)	-2.4 (± 6.6)	
VISIT 5 (WEEK 26), PREDOSE	-4.2 (± 8.2)	-4.1 (± 10.4)	-2.4 (± 7.6)	

Notes:

[20] - n=48 for week 7, n=45 for week 14 and n=44 for week 26

[21] - n=50 for week 7, n=47 for week 14 and n=45 for week 26

[22] - n=50 for week 7, n=49 for week 14 and n=46 for week 26

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
Statistical analysis description:	
The relative (%) change from baseline in fasting glucose after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5665
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
Statistical analysis description:	
The relative (%) change from baseline in fasting glucose after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4785
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
Statistical analysis description:	
The relative (%) change from baseline in fasting glucose after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
The total number of subjects included in this analysis was 94 (the number 98 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.208
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
Statistical analysis description:	
The relative (%) change from baseline in fasting glucose after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
The total number of subjects included in this analysis was 96 (the number 100 refers to week 7).	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2512
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
Statistical analysis description:	
The relative (%) change from baseline in fasting glucose after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
The total number of subjects included in this analysis was 90 (the number 98 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4333
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
Statistical analysis description:	
The relative (%) change from baseline in fasting glucose after 26 weeks of treatment with EMP16-	

150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in this analysis was 91 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4537
Method	ANOVA

Secondary: Relative (%) change from baseline in fasting hemoglobin A1C (HbA1c) after 7, 14 and 26 weeks

End point title	Relative (%) change from baseline in fasting hemoglobin A1C (HbA1c) after 7, 14 and 26 weeks
-----------------	--

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean relative (%) change from baseline in fasting hemoglobin A1C (HbA1c) after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[23]	50 ^[24]	50 ^[25]	
Units: percent				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	-3.9 (± 5.7)	-2.5 (± 4.6)	-1.7 (± 3.9)	
VISIT 4 (WEEK 14), PREDOSE	-2.1 (± 5.5)	-0.6 (± 5.3)	0.2 (± 5.3)	
VISIT 5 (WEEK 26), PREDOSE	-3.1 (± 5.8)	-2.8 (± 6.1)	-1.5 (± 5.8)	

Notes:

[23] - n=48 for week 7, n=45 for week 14 and n=44 for week 26

[24] - n=50 for week 7, n=47 for week 14 and n=45 for week 26

[25] - n=50 for week 7, n=49 for week 14 and n=46 for week 26

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
----------------------------	---------------------------------------

Statistical analysis description:

The relative (%) change from baseline in fasting HbA1c after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.022
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
-----------------------------------	---------------------------------------

Statistical analysis description:

The relative (%) change from baseline in fasting HbA1c after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3992
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting HbA1c after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 94 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0252
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting HbA1c after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 96 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3543
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting HbA1c after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0753
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting HbA1c after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 91 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1711
Method	ANOVA

Secondary: Relative (%) change from baseline in fasting insulin after 7, 14 and 26 weeks

End point title	Relative (%) change from baseline in fasting insulin after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean relative (%) change from baseline in fasting insulin after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
End point timeframe:	
Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[26]	49 ^[27]	50 ^[28]	
Units: percent				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	-15.0 (± 29.7)	-13.6 (± 37.4)	-8.0 (± 33.2)	
VISIT 4 (WEEK 14), PREDOSE	-15.9 (± 32.1)	-13.7 (± 39.1)	5.1 (± 49.6)	
VISIT 5 (WEEK 26), PREDOSE	-9.1 (± 35.8)	7.5 (± 106.9)	0.6 (± 48.8)	

Notes:

[26] - n=48 for week 7, n=45 for week 14 and n=44 for week 26

[27] - n=49 for week 7, n=46 for week 14 and n=43 for week 26

[28] - n=50 for week 7, n=49 for week 14 and n=46 for week 26

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
Statistical analysis description:	
The relative (%) change from baseline in fasting insulin after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3037
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
Statistical analysis description:	
The relative (%) change from baseline in fasting insulin after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4097
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
Statistical analysis description:	
The relative (%) change from baseline in fasting insulin after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
The total number of subjects included in the analysis was 94 (the number 98 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0096
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
Statistical analysis description:	
The relative (%) change from baseline in fasting insulin after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
The total number of subjects included in the analysis was 95 (the number 99 refers to week 7).	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0192
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
Statistical analysis description:	
The relative (%) change from baseline in fasting insulin after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4187
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
Statistical analysis description:	
The relative (%) change from baseline in fasting insulin after 26 weeks of treatment with EMP16-150/50	

as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 90 (the number 99 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.7561
Method	ANOVA

Secondary: Relative (%) change from baseline in fasting triglycerides after 7, 14 and 26 weeks

End point title	Relative (%) change from baseline in fasting triglycerides after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean relative (%) change from baseline in fasting triglycerides after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[29]	50 ^[30]	49 ^[31]	
Units: percent				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	7.3 (± 32.8)	6.3 (± 41.0)	-3.6 (± 29.0)	
VISIT 4 (WEEK 14), PREDOSE	-2.5 (± 28.3)	1.2 (± 38.4)	-8.3 (± 36.2)	
VISIT 5 (WEEK 26), PREDOSE	2.4 (± 37.6)	5.0 (± 46.0)	-8.6 (± 28.3)	

Notes:

[29] - n=48 for week 7, n=45 for week 14 and n=44 for week 26

[30] - n=50 for week 7, n=47 for week 14 and n=45 for week 26

[31] - n=49 for week 7, n=49 for week 14 and n=46 for week 26

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
----------------------------	---------------------------------------

Statistical analysis description:

The relative (%) change from baseline in fasting triglycerides after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1252
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
-----------------------------------	---------------------------------------

Statistical analysis description:

The relative (%) change from baseline in fasting triglycerides after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1613
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting triglycerides after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in this analysis was 94 (the number 97 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6082
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting triglycerides after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in this analysis was 96 (the number 99 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1851
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting triglycerides after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in this analysis was 90 (the number 97 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.368
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting triglycerides after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in this analysis was 91 (the number 99 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.122
Method	ANOVA

Secondary: Relative (%) change from baseline in fasting LDL cholesterol after 7, 14 and 26 weeks

End point title	Relative (%) change from baseline in fasting LDL cholesterol after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean relative (%) change from baseline in fasting low-density lipoprotein (LDL) cholesterol after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
End point timeframe:	
Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[32]	50 ^[33]	50 ^[34]	
Units: percent				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	-12.2 (± 13.0)	-9.5 (± 13.3)	0.1 (± 16.8)	
VISIT 4 (WEEK 14), PREDOSE	-13.8 (± 12.8)	-9.0 (± 19.5)	-3.1 (± 17.7)	
VISIT 5 (WEEK 26), PREDOSE	-8.8 (± 13.7)	-7.4 (± 15.3)	1.8 (± 18.5)	

Notes:

[32] - n=48 for week 7, n=45 for week 14 and n=44 for week 26

[33] - n=50 for week 7, n=47 for week 14 and n=45 for week 26

[34] - n=50 for week 7, n=49 for week 14 and n=46 for week 26

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
Statistical analysis description:	
The relative (%) change from baseline in fasting LDL cholesterol after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0001
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
Statistical analysis description:	
The relative (%) change from baseline in fasting LDL cholesterol after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	Placebo v EMP16-02 - 150/50
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0012
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
Statistical analysis description:	
The relative (%) change from baseline in fasting LDL cholesterol after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
The total number of subjects included in the analysis was 94 (the number 98 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0038
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
Statistical analysis description:	
The relative (%) change from baseline in fasting LDL cholesterol after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
The total number of subjects included in the analysis was 96 (the number 100 refers to week 7).	
Comparison groups	Placebo v EMP16-02 - 150/50
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.082
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
Statistical analysis description:	
The relative (%) change from baseline in fasting LDL cholesterol after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0017
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
Statistical analysis description:	
The relative (%) change from baseline in fasting LDL cholesterol after 26 weeks of treatment with	

EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 91 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0028
Method	ANOVA

Secondary: Relative (%) change from baseline in fasting HDL cholesterol after 7, 14 and 26 weeks

End point title	Relative (%) change from baseline in fasting HDL cholesterol after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean relative (%) change from baseline in fasting high-density lipoprotein (HDL) cholesterol after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[35]	50 ^[36]	50 ^[37]	
Units: percent				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	-10.4 (± 10.4)	-11.2 (± 10.8)	2.5 (± 14.4)	
VISIT 4 (WEEK 14), PREDOSE	-9.8 (± 11.3)	-13.5 (± 11.4)	-0.8 (± 13.1)	
VISIT 5 (WEEK 26), PREDOSE	-7.6 (± 12.0)	-10.9 (± 12.3)	-0.3 (± 12.8)	

Notes:

[35] - n=48 for week 7, n=45 for week 14 and n=44 for week 26

[36] - n=50 for week 7, n=47 for week 14 and n=45 for week 26

[37] - n=50 for week 7, n=49 for week 14 and n=46 for week 26

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
----------------------------	---------------------------------------

Statistical analysis description:

The relative (%) change from baseline in fasting HDL cholesterol after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
-----------------------------------	---------------------------------------

Statistical analysis description:

The relative (%) change from baseline in fasting HDL cholesterol after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting HDL cholesterol after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in this analysis was 94 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0005
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting HDL cholesterol after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in this analysis was 96 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting HDL cholesterol after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in this analysis was 90 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0038
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting HDL cholesterol after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in this analysis was 91 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANOVA

Secondary: Relative (%) change from baseline in fasting total cholesterol after 7, 14 and 26 weeks

End point title	Relative (%) change from baseline in fasting total cholesterol after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean relative (%) change from baseline in fasting total cholesterol after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
End point timeframe:	
Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[38]	50 ^[39]	50 ^[40]	
Units: percent				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	-9.4 (± 10.9)	-8.8 (± 10.2)	0.4 (± 10.1)	
VISIT 4 (WEEK 14), PREDOSE	-12.2 (± 10.5)	-9.7 (± 12.7)	-3.6 (± 11.1)	
VISIT 5 (WEEK 26), PREDOSE	-8.6 (± 11.4)	-8.0 (± 12.5)	-2.2 (± 11.3)	

Notes:

[38] - n=48 for week 7, n=45 for week 14 and n=44 for week 26.

[39] - n=50 for week 7, n=47 for week 14 and n=45 for week 26.

[40] - n=50 for week 7, n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
Statistical analysis description:	
The relative (%) change from baseline in fasting total cholesterol after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
Statistical analysis description:	
The relative (%) change from baseline in fasting total cholesterol after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
Statistical analysis description:	
The relative (%) change from baseline in fasting total cholesterol after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
The total number of subjects included in the analysis was 94 (the number 98 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0003
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
Statistical analysis description:	
The relative (%) change from baseline in fasting total cholesterol after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
The total number of subjects included in the analysis was 96 (the number 100 refers to week 7).	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0047
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
Statistical analysis description:	
The relative (%) change from baseline in fasting total cholesterol after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.002
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting total cholesterol after 26 weeks of treatment with

EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0021
Method	ANOVA

Secondary: Relative (%) change from baseline in fasting hs-CRP after 7, 14 and 26 weeks

End point title	Relative (%) change from baseline in fasting hs-CRP after 7, 14 and 26 weeks
-----------------	--

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean relative (%) change from baseline in fasting high-sensitivity C-reactive protein (hs-CRP) after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[41]	50 ^[42]	50 ^[43]	
Units: percent				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	26.5 (± 200.5)	10.2 (± 91.7)	42.2 (± 321.7)	
VISIT 4 (WEEK 14), PREDOSE	-5.6 (± 60.5)	12.6 (± 134.3)	38.2 (± 241.1)	
VISIT 5 (WEEK 26), PREDOSE	7.2 (± 106.0)	-19.5 (± 37.0)	5.8 (± 65.8)	

Notes:

[41] - n=48 for week 7, n=45 for week 14 and n=44 for week 26.

[42] - n=50 for week 7, n=47 for week 14 and n=45 for week 26.

[43] - n=50 for week 7, n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
----------------------------	---------------------------------------

Statistical analysis description:

The relative (%) change from baseline in fasting hs-CRP after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7314
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
-----------------------------------	---------------------------------------

Statistical analysis description:

The relative (%) change from baseline in fasting hs-CRP after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4793
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting hs-CRP after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 94 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2511
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting hs-CRP after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 96 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.425
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting hs-CRP after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6908
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting hs-CRP after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 91 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0665
Method	ANOVA

Secondary: Absolute change from baseline in fasting albumin after 7, 14 and 26 weeks

End point title	Absolute change from baseline in fasting albumin after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean absolute change from baseline in fasting albumin after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
End point timeframe:	
Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[44]	50 ^[45]	50 ^[46]	
Units: g/L				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	0.5 (± 3.0)	0.6 (± 2.8)	-0.2 (± 2.5)	
VISIT 4 (WEEK 14), PREDOSE	-0.6 (± 1.9)	-1.0 (± 2.9)	-1.4 (± 2.1)	
VISIT 5 (WEEK 26), PREDOSE	-0.2 (± 2.4)	-0.2 (± 2.9)	-0.3 (± 2.4)	

Notes:

[44] - n=48 for week 7, n=45 for week 14 and n=44 for week 26.

[45] - n=50 for week 7, n=47 for week 14 and n=45 for week 26.

[46] - n=50 for week 7, n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
Statistical analysis description:	
The absolute change from baseline in fasting albumin after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1607
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
Statistical analysis description:	
The absolute change from baseline in fasting albumin after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
Comparison groups	Placebo v EMP16-02 - 150/50
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1098
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
----------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting albumin after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 94 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0775
Method	ANCOVA

Statistical analysis title

EMP16-02 - 150/50 VS placebo - Week 14

Statistical analysis description:

The absolute change from baseline in fasting albumin after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 96 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3853
Method	ANCOVA

Statistical analysis title

EMP16-02 - 120/40 VS placebo - Week 26

Statistical analysis description:

The absolute change from baseline in fasting albumin after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9178
Method	ANCOVA

Statistical analysis title

EMP16-02 - 150/50 VS placebo - Week 26

Statistical analysis description:

The absolute change from baseline in fasting albumin after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 91 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9943
Method	ANCOVA

Secondary: Absolute change from baseline in fasting glucose after 7, 14 and 26 weeks

End point title	Absolute change from baseline in fasting glucose after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean absolute change from baseline in fasting glucose after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[47]	50 ^[48]	50 ^[49]	
Units: mmol/L				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	-0.16 (± 0.45)	-0.17 (± 0.63)	-0.10 (± 0.40)	
VISIT 4 (WEEK 14), PREDOSE	-0.30 (± 0.50)	-0.27 (± 0.55)	-0.15 (± 0.45)	
VISIT 5 (WEEK 26), PREDOSE	-0.27 (± 0.50)	-0.26 (± 0.65)	-0.16 (± 0.49)	

Notes:

[47] - n=48 for week 7, n=45 for week 14 and n=44 for week 26.

[48] - n=50 for week 7, n=47 for week 14 and n=45 for week 26.

[49] - n=50 for week 7, n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
----------------------------	---------------------------------------

Statistical analysis description:

The absolute change from baseline in fasting glucose after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

Comparison groups	EMP16-02 - 120/40 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.478
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
-----------------------------------	---------------------------------------

Statistical analysis description:

The absolute change from baseline in fasting glucose after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.426
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting glucose after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 94 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1858
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting glucose after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 96 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2475
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
Statistical analysis description:	
The absolute change from baseline in fasting glucose after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3422
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
Statistical analysis description:	
The absolute change from baseline in fasting glucose after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
The total number of subjects included in the analysis was 91 (the number 100 refers to week 7).	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3651
Method	ANCOVA

Secondary: Absolute change from baseline in fasting hemoglobin A1C (HbA1c) after 7, 14 and 26 weeks

End point title	Absolute change from baseline in fasting hemoglobin A1C (HbA1c) after 7, 14 and 26 weeks
End point description:	
Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean absolute change from baseline in fasting hemoglobin A1C (HbA1c) after 7, 14 and 26 weeks of treatment.	
The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.	
End point type	Secondary
End point timeframe:	
Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[50]	50 ^[51]	50 ^[52]	
Units: mmol/mol				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	-1.5 (± 2.3)	-0.9 (± 1.7)	-0.7 (± 1.4)	
VISIT 4 (WEEK 14), PREDOSE	-0.9 (± 2.3)	-0.3 (± 1.9)	0.0 (± 1.9)	
VISIT 5 (WEEK 26), PREDOSE	-1.2 (± 2.3)	-1.1 (± 2.4)	-0.6 (± 2.2)	

Notes:

[50] - n=48 for week 7, n=45 for week 14 and n=44 for week 26.

[51] - n=50 for week 7, n=47 for week 14 and n=45 for week 26.

[52] - n=50 for week 7, n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
Statistical analysis description:	
The absolute change from baseline in fasting HbA1c after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0283
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
Statistical analysis description:	
The absolute change from baseline in fasting HbA1c after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5118
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
Statistical analysis description:	
The absolute change from baseline in fasting HbA1c after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	

The total number of subjects included in the analysis was 94 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0667
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting HbA1c after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 96 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5837
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting HbA1c after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2908
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting HbA1c after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 91 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3418
Method	ANCOVA

Secondary: Absolute change from baseline in fasting insulin after 7, 14 and 26 weeks

End point title	Absolute change from baseline in fasting insulin after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean absolute change from baseline in fasting insulin after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[53]	49 ^[54]	50 ^[55]	
Units: mIU/L				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	-3.958 (± 8.125)	-3.129 (± 8.642)	-3.320 (± 10.68)	
VISIT 4 (WEEK 14), PREDOSE	-4.222 (± 7.674)	-3.241 (± 7.919)	-0.01020 (± 11.83)	
VISIT 5 (WEEK 26), PREDOSE	-3.620 (± 9.705)	0.07907 (± 18.10)	-1.509 (± 8.411)	

Notes:

[53] - n=48 for week 7, n=45 for week 14 and n=44 for week 26.

[54] - n=49 for week 7, n=46 for week 14 and n=43 for week 26.

[55] - n=50 for week 7, n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
Statistical analysis description:	
The absolute change from baseline in fasting insulin after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
Comparison groups	EMP16-02 - 120/40 v Placebo

Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6382
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
-----------------------------------	---------------------------------------

Statistical analysis description:

The absolute change from baseline in fasting insulin after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9784
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting insulin after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in this analysis was 94 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0358
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting insulin after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in this analysis was 95 (the number 99 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1012
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
Statistical analysis description:	
The absolute change from baseline in fasting insulin after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
The total number of subjects included in this analysis was 90 (the number 98 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3965
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
Statistical analysis description:	
The absolute change from baseline in fasting insulin after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
The total number of subjects included in this analysis was 89 (the number 99 refers to week 7).	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5905
Method	ANCOVA

Secondary: Absolute change from baseline in fasting triglycerides after 7, 14 and 26 weeks

End point title	Absolute change from baseline in fasting triglycerides after 7, 14 and 26 weeks
End point description:	
Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean absolute change from baseline in fasting triglycerides after 7, 14 and 26 weeks of treatment.	
The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.	
End point type	Secondary
End point timeframe:	
Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[56]	50 ^[57]	49 ^[58]	
Units: mmol/L				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	0.011 (± 0.632)	-0.047 (± 0.619)	-0.149 (± 0.659)	
VISIT 4 (WEEK 14), PREDOSE	-0.116 (± 0.483)	-0.070 (± 0.623)	-0.275 (± 0.732)	
VISIT 5 (WEEK 26), PREDOSE	-0.092 (± 0.642)	-0.028 (± 0.626)	-0.237 (± 0.784)	

Notes:

[56] - n=48 for week 7, n=45 for week 14 and n=44 for week 26.

[57] - n=50 for week 7, n=47 for week 14 and n=45 for week 26.

[58] - n=49 for week 7, n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
Statistical analysis description:	
The absolute change from baseline in fasting triglycerides after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2494
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
Statistical analysis description:	
The absolute change from baseline in fasting triglycerides after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4506
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
----------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting triglycerides after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 94 (the number 97 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3274
Method	ANCOVA

Statistical analysis title

EMP16-02 - 150/50 VS placebo - Week 14

Statistical analysis description:

The absolute change from baseline in fasting triglycerides after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 96 (the number 99 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1452
Method	ANCOVA

Statistical analysis title

EMP16-02 - 120/40 VS placebo - Week 26

Statistical analysis description:

The absolute change from baseline in fasting triglycerides after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 90 (the number 97 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4394
Method	ANCOVA

Statistical analysis title

EMP16-02 - 150/50 VS placebo - Week 26

Statistical analysis description:

The absolute change from baseline in fasting triglycerides after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 91 (the number 99 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1912
Method	ANCOVA

Secondary: Absolute change from baseline in fasting LDL cholesterol after 7, 14 and 26 weeks

End point title	Absolute change from baseline in fasting LDL cholesterol after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean absolute change from baseline in fasting low-density lipoprotein (LDL) cholesterol after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[59]	50 ^[60]	50 ^[61]	
Units: mmol/L				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	-0.49 (± 0.52)	-0.34 (± 0.52)	-0.05 (± 0.51)	
VISIT 4 (WEEK 14), PREDOSE	-0.51 (± 0.46)	-0.36 (± 0.66)	-0.14 (± 0.51)	
VISIT 5 (WEEK 26), PREDOSE	-0.34 (± 0.52)	-0.26 (± 0.61)	0.01 (± 0.55)	

Notes:

[59] - n=48 for week 7, n=45 for week 14 and n=44 for week 26.

[60] - n=50 for week 7, n=47 for week 14 and n=45 for week 26.

[61] - n=50 for week 7, n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
----------------------------	---------------------------------------

Statistical analysis description:

The absolute change from baseline in fasting LDL cholesterol after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

Comparison groups	EMP16-02 - 120/40 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
-----------------------------------	---------------------------------------

Statistical analysis description:

The absolute change from baseline in fasting LDL cholesterol after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

Comparison groups	Placebo v EMP16-02 - 150/50
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0051
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting LDL cholesterol after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 94 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.001
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting LDL cholesterol after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 96 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0473
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
Statistical analysis description:	
The absolute change from baseline in fasting LDL cholesterol after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0024
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
Statistical analysis description:	
The absolute change from baseline in fasting LDL cholesterol after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
The total number of subjects included in the analysis was 91 (the number 100 refers to week 7).	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0203
Method	ANCOVA

Secondary: Absolute change from baseline in fasting HDL cholesterol after 7, 14 and 26 weeks

End point title	Absolute change from baseline in fasting HDL cholesterol after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean absolute change from baseline in fasting high-density lipoprotein (HDL) cholesterol after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[62]	50 ^[63]	50 ^[64]	
Units: mmol/L				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	-0.15 (± 0.14)	-0.16 (± 0.16)	0.03 (± 0.19)	
VISIT 4 (WEEK 14), PREDOSE	-0.14 (± 0.15)	-0.20 (± 0.19)	-0.02 (± 0.19)	
VISIT 5 (WEEK 26), PREDOSE	-0.11 (± 0.16)	-0.16 (± 0.19)	-0.02 (± 0.18)	

Notes:

[62] - n=48 for week 7, n=45 for week 14 and n=44 for week 26.

[63] - n=50 for week 7, n=47 for week 14 and n=45 for week 26.

[64] - n=50 for week 7, n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
Statistical analysis description:	
The absolute change from baseline in fasting HDL cholesterol after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
Statistical analysis description:	
The absolute change from baseline in fasting HDL cholesterol after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
Statistical analysis description:	
The absolute change from baseline in fasting HDL cholesterol after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	

The total number of subjects included in the analysis was 94 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0015
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting HDL cholesterol after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 96 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting HDL cholesterol after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0253
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting HDL cholesterol after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 91 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0001
Method	ANCOVA

Secondary: Absolute change from baseline in fasting cholesterol after 7, 14 and 26 weeks

End point title	Absolute change from baseline in fasting cholesterol after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean absolute change from baseline in fasting total cholesterol after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[65]	50 ^[66]	50 ^[67]	
Units: mmol/L				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	-0.59 (± 0.82)	-0.48 (± 0.59)	0.00 (± 0.53)	
VISIT 4 (WEEK 14), PREDOSE	-0.72 (± 0.70)	-0.56 (± 0.76)	-0.22 (± 0.56)	
VISIT 5 (WEEK 26), PREDOSE	-0.53 (± 0.73)	-0.45 (± 0.76)	-0.13 (± 0.59)	

Notes:

[65] - n=48 for week 7, n=45 for week 14 and n=44 for week 26.

[66] - n=50 for week 7, n=47 for week 14 and n=45 for week 26.

[67] - n=50 for week 7, n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
----------------------------	---------------------------------------

Statistical analysis description:

The absolute change from baseline in fasting total cholesterol after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

Comparison groups	EMP16-02 - 120/40 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
-----------------------------------	---------------------------------------

Statistical analysis description:

The absolute change from baseline in fasting total cholesterol after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0005
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting total cholesterol after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 94 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0004
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting total cholesterol after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 91 (the number 100 refers to week 7).

Comparison groups	Placebo v EMP16-02 - 150/50
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0142
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
Statistical analysis description:	
The absolute change from baseline in fasting total cholesterol after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0069
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
Statistical analysis description:	
The absolute change from baseline in fasting total cholesterol after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
The total number of subjects included in the analysis was 91 (the number 100 refers to week 7).	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0297
Method	ANCOVA

Secondary: Absolute change from baseline in fasting hs-CRP after 7, 14 and 26 weeks

End point title	Absolute change from baseline in fasting hs-CRP after 7, 14 and 26 weeks
End point description:	
Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean absolute change from baseline in fasting high-sensitivity C-reactive protein (hs-CRP) after 7, 14 and 26 weeks of treatment.	
The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.	
End point type	Secondary
End point timeframe:	
Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[68]	50 ^[69]	50 ^[70]	
Units: mg/L				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	-0.7 (± 3.2)	0.1 (± 2.6)	-0.2 (± 7.5)	
VISIT 4 (WEEK 14), PREDOSE	-0.7 (± 3.1)	-0.7 (± 2.8)	-0.3 (± 7.3)	
VISIT 5 (WEEK 26), PREDOSE	0.7 (± 11.0)	-1.1 (± 2.0)	-0.6 (± 6.6)	

Notes:

[68] - n=48 for week 7, n=45 for week 14 and n=44 for week 26.

[69] - n=50 for week 7, n=47 for week 14 and n=45 for week 26.

[70] - n=50 for week 7, n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
Statistical analysis description:	
The absolute change from baseline in fasting hs-CRP after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7331
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
Statistical analysis description:	
The absolute change from baseline in fasting hs-CRP after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6953
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
Statistical analysis description:	
The absolute change from baseline in fasting hs-CRP after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	

The total number of subjects included in the analysis was 94 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8853
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting hs-CRP after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 96 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7778
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting hs-CRP after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3464
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting hs-CRP after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 91 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8254
Method	ANCOVA

Secondary: Relative (%) change from baseline in fasting ALT after 7, 14 and 26 weeks

End point title	Relative (%) change from baseline in fasting ALT after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean relative (%) change from baseline in fasting alanine aminotransferase (ALT) after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[71]	50 ^[72]	50 ^[73]	
Units: percent				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	10.8 (± 51.5)	8.0 (± 38.5)	-6.7 (± 27.6)	
VISIT 4 (WEEK 14), PREDOSE	3.0 (± 35.3)	17.6 (± 85.5)	-3.2 (± 55.6)	
VISIT 5 (WEEK 26), PREDOSE	-4.5 (± 36.9)	3.6 (± 49.6)	-7.7 (± 27.9)	

Notes:

[71] - n=48 for week 7, n=45 for week 14 and n=44 for week 26.

[72] - n=50 for week 7, n=46 for week 14 and n=45 for week 26.

[73] - n=50 for week 7, n=46 for week 14 and n=45 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
----------------------------	---------------------------------------

Statistical analysis description:

The relative (%) change from baseline in fasting ALT after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 120/40 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0333
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
-----------------------------------	---------------------------------------

Statistical analysis description:

The relative (%) change from baseline in fasting ALT after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0707
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting ALT after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 94 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6289
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting ALT after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 95 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1126
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting ALT after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9673
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting ALT after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 91 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6607
Method	ANOVA

Secondary: Relative (%) change from baseline in fasting AST after 7, 14 and 26 weeks

End point title	Relative (%) change from baseline in fasting AST after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean relative (%) change from baseline in fasting aspartate aminotransferase (AST) after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
End point timeframe:	
Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	47 ^[74]	50 ^[75]	48 ^[76]	
Units: percent				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	4.2 (± 28.7)	4.9 (± 26.1)	-2.7 (± 31.8)	
VISIT 4 (WEEK 14), PREDOSE	-4.5 (± 21.2)	22.5 (± 183.8)	-11.2 (± 22.2)	
VISIT 5 (WEEK 26), PREDOSE	-7.3 (± 22.2)	0.9 (± 34.4)	-4.5 (± 27.6)	

Notes:

[74] - n=47 for week 7, n=44 for week 14 and n=43 for week 26.

[75] - n=50 for week 7, n=46 for week 14 and n=45 for week 26.

[76] - n=48 for week 7, n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
Statistical analysis description:	
The relative (%) change from baseline in fasting AST after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	95
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2479
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
Statistical analysis description:	
The relative (%) change from baseline in fasting AST after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1949
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
Statistical analysis description:	
The relative (%) change from baseline in fasting AST after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
The total number of subjects included in the analysis was 93 (the number 95 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	95
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7191
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
Statistical analysis description:	
The relative (%) change from baseline in fasting AST after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
The total number of subjects included in the analysis was 95 (the number 98 refers to week 7).	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1281
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
Statistical analysis description:	
The relative (%) change from baseline in fasting AST after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
The total number of subjects included in the analysis was 89 (the number 95 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	95
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8387
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting AST after 26 weeks of treatment with EMP16-150/50 as

compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 91 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3571
Method	ANOVA

Secondary: Relative (%) change from baseline in fasting ALP after 7, 14 and 26 weeks

End point title	Relative (%) change from baseline in fasting ALP after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean relative (%) change from baseline in fasting alkaline phosphatase (ALP) after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[77]	50 ^[78]	50 ^[79]	
Units: percent				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	3.3 (± 10.4)	0.6 (± 10.7)	-0.8 (± 10.9)	
VISIT 4 (WEEK 14), PREDOSE	3.8 (± 10.7)	1.0 (± 13.8)	-0.9 (± 12.3)	
VISIT 5 (WEEK 26), PREDOSE	8.5 (± 14.9)	3.7 (± 15.1)	2.4 (± 11.4)	

Notes:

[77] - n=48 for week 7, n=45 for week 14 and n=44 for week 26.

[78] - n=50 for week 7, n=46 for week 14 and n=45 for week 26.

[79] - n=50 for week 7, n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
----------------------------	---------------------------------------

Statistical analysis description:

The relative (%) change from baseline in fasting ALP after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0608
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
-----------------------------------	---------------------------------------

Statistical analysis description:

The relative (%) change from baseline in fasting ALP after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5028
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting ALP after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 94 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0717
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting ALP after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 95 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3449
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting ALP after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0618
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting ALP after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 91 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.916
Method	ANOVA

Secondary: Relative (%) change from baseline in fasting GGT after 7, 14 and 26 weeks

End point title	Relative (%) change from baseline in fasting GGT after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean relative (%) change from baseline in fasting gamma glutamyl transferase (GGT) after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
End point timeframe:	
Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[80]	50 ^[81]	50 ^[82]	
Units: percent				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	-5.3 (± 21.1)	-6.1 (± 20.2)	-1.5 (± 28.3)	
VISIT 4 (WEEK 14), PREDOSE	-10.5 (± 41.6)	-2.0 (± 46.1)	-1.6 (± 44.0)	
VISIT 5 (WEEK 26), PREDOSE	-9.6 (± 38.2)	-12.2 (± 23.5)	-2.0 (± 31.7)	

Notes:

[80] - n=48 for week 7, n=45 for week 14 and n=44 for week 26.

[81] - n=50 for week 7, n=46 for week 14 and n=45 for week 26.

[82] - n=50 for week 7, n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
Statistical analysis description:	
The relative (%) change from baseline in fasting GGT after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4247
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
Statistical analysis description:	
The relative (%) change from baseline in fasting GGT after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3328
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
Statistical analysis description:	
The relative (%) change from baseline in fasting GGT after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
The total number of subjects included in the analysis was 94 (the number 98 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3522
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
Statistical analysis description:	
The relative (%) change from baseline in fasting GGT after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
The total number of subjects included in the analysis was 95 (the number 100 refers to week 7).	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8695
Method	ANOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
Statistical analysis description:	
The relative (%) change from baseline in fasting GGT after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1313
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in fasting GGT after 26 weeks of treatment with EMP16-150/50

as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

The total number of subjects included in the analysis was 91 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0334
Method	ANOVA

Secondary: Absolute change from baseline in fasting ALT after 7, 14 and 26 weeks

End point title	Absolute change from baseline in fasting ALT after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean absolute change from baseline in fasting alanine aminotransferase (ALT) after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[83]	50 ^[84]	50 ^[85]	
Units: ukat/L				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	0.024 (± 0.242)	0.020 (± 0.234)	-0.056 (± 0.188)	
VISIT 4 (WEEK 14), PREDOSE	-0.026 (± 0.204)	0.043 (± 0.366)	-0.063 (± 0.202)	
VISIT 5 (WEEK 26), PREDOSE	-0.057 (± 0.217)	-0.015 (± 0.313)	-0.069 (± 0.151)	

Notes:

[83] - n=48 for week 7, n=45 for week 14 and n=44 for week 26.

[84] - n=50 for week 7, n=46 for week 14 and n=45 for week 26.

[85] - n=50 for week 7, n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
----------------------------	---------------------------------------

Statistical analysis description:

The absolute change from baseline in fasting ALT after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body

weight at baseline as covariate.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0735
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
-----------------------------------	---------------------------------------

Statistical analysis description:

The absolute change from baseline in fasting ALT after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0878
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting ALT after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 94 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4925
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting ALT after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 95 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0555
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting ALT after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8744
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting ALT after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 91 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3057
Method	ANCOVA

Secondary: Absolute change from baseline in fasting AST after 7, 14 and 26 weeks

End point title	Absolute change from baseline in fasting AST after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean absolute change from baseline in fasting aspartate aminotransferase (AST) after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	47 ^[86]	50 ^[87]	48 ^[88]	
Units: ukat/L				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	0.010 (± 0.127)	0.011 (± 0.128)	-0.040 (± 0.150)	
VISIT 4 (WEEK 14), PREDOSE	-0.034 (± 0.105)	0.076 (± 0.721)	-0.072 (± 0.143)	
VISIT 5 (WEEK 26), PREDOSE	-0.046 (± 0.112)	-0.012 (± 0.138)	-0.037 (± 0.137)	

Notes:

[86] - n=47 for week 7, n=44 for week 14 and n=43 for week 26.

[87] - n=50 for week 7, n=46 for week 14 and n=45 for week 26.

[88] - n=48 for week 7, n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
Statistical analysis description: The absolute change from baseline in fasting AST after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	95
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0915
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
Statistical analysis description: The absolute change from baseline in fasting AST after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0674
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
Statistical analysis description:	
The absolute change from baseline in fasting AST after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
The total number of subjects included in the analysis was 93 (the number 95 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	95
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6081
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
Statistical analysis description:	
The absolute change from baseline in fasting AST after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
The total number of subjects included in the analysis was 95 (the number 98 refers to week 7).	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0863
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
Statistical analysis description:	
The absolute change from baseline in fasting AST after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
The total number of subjects included in the analysis was 89 (the number 95 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	95
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6796
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
Statistical analysis description:	
The absolute change from baseline in fasting AST after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	

The total number of subjects included in the analysis was 91 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3852
Method	ANCOVA

Secondary: Absolute change from baseline in fasting ALP after 7, 14 and 26 weeks

End point title	Absolute change from baseline in fasting ALP after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean absolute change from baseline in fasting alkaline phosphatase (ALP) after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[89]	50 ^[90]	50 ^[91]	
Units: ukat/L				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	0.031 (± 0.136)	-0.003 (± 0.128)	-0.016 (± 0.121)	
VISIT 4 (WEEK 14), PREDOSE	0.035 (± 0.135)	-0.001 (± 0.163)	-0.021 (± 0.141)	
VISIT 5 (WEEK 26), PREDOSE	0.090 (± 0.178)	0.036 (± 0.178)	0.013 (± 0.134)	

Notes:

[89] - n=48 for week 7, n=45 for week 14 and n=44 for week 26.

[90] - n=50 for week 7, n=46 for week 14 and n=45 for week 26.

[91] - n=50 for week 7, n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
----------------------------	---------------------------------------

Statistical analysis description:

The absolute change from baseline in fasting ALP after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

Comparison groups	Placebo v EMP16-02 - 120/40
-------------------	-----------------------------

Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0675
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
-----------------------------------	---------------------------------------

Statistical analysis description:

The absolute change from baseline in fasting ALP after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5983
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting ALP after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 94 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0823
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting ALP after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 95 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5335
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
Statistical analysis description:	
The absolute change from baseline in fasting ALP after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0367
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
Statistical analysis description:	
The absolute change from baseline in fasting ALP after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
The total number of subjects included in the analysis was 91 (the number 100 refers to week 7).	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5585
Method	ANCOVA

Secondary: Absolute change from baseline in fasting GGT after 7, 14 and 26 weeks

End point title	Absolute change from baseline in fasting GGT after 7, 14 and 26 weeks
-----------------	---

End point description:

Venous blood samples (4 mL) were collected to analyze the fasting profile of lipid metabolism markers, glucose metabolism markers, and inflammation markers. All parameters were analyzed in immediate association with sampling. This end-point reports the mean absolute change from baseline in fasting gamma glutamyl transferase (GGT) after 7, 14 and 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood sampling for analysis was done at Visit 2 (Day 1, baseline), Visit 3 (Week 7), Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	48 ^[92]	50 ^[93]	50 ^[94]	
Units: ukat/L				
arithmetic mean (standard deviation)				
VISIT 3 (WEEK 7), PREDOSE	-0.02958 (± 0.1519)	-0.04700 (± 0.1923)	-0.09420 (± 0.4697)	
VISIT 4 (WEEK 14), PREDOSE	-0.06933 (± 0.1948)	-0.01826 (± 0.2228)	-0.09367 (± 0.4742)	
VISIT 5 (WEEK 26), PREDOSE	-0.07318 (± 0.2006)	-0.07111 (± 0.1611)	-0.1226 (± 0.5147)	

Notes:

[92] - n=48 for week 7, n=45 for week 14 and n=44 for week 26.

[93] - n=50 for week 7, n=46 for week 14 and n=45 for week 26.

[94] - n=50 for week 7, n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
Statistical analysis description:	
The absolute change from baseline in fasting GGT after 7 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.22
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
Statistical analysis description:	
The absolute change from baseline in fasting GGT after 7 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3775
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
Statistical analysis description:	
The absolute change from baseline in fasting GGT after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.	
The total number of subjects included in the analysis was 94 (the number 98 refers to week 7).	

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6703
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting GGT after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 95 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2478
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting GGT after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 90 (the number 98 refers to week 7).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4007
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in fasting GGT after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 91 (the number 100 refers to week 7).

Comparison groups	EMP16-02 - 150/50 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.41
Method	ANCOVA

Secondary: Diabetic status at baseline, week 14 and week 26

End point title	Diabetic status at baseline, week 14 and week 26
End point description:	
Diabetic status was defined as fasting glucose ≥ 7.0 mmol/L and prediabetic status was defined as fasting glucose ≥ 6.1 mmol/L and < 7.0 mmol/L. This end-point reports the proportions (%) of diabetic, non-diabetic and prediabetic patients at baseline (Week 1, Day 1), Week 14 and Week 26.	
The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.	
End point type	Secondary
End point timeframe:	
Blood sampling for analysis of fasting glucose was done at Visit 2 (Day 1, baseline), Visit 4 (Week 14) and Visit 5 (Week 26).	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	52 ^[95]	52 ^[96]	52 ^[97]	
Units: percent				
number (not applicable)				
VISIT 2 (WEEK 1), PREDOSE - Diabetic	9.6	3.8	9.6	
VISIT 2 (WEEK 1), PREDOSE - Non-diabetic	65	69	54	
VISIT 2 (WEEK 1), PREDOSE - Prediabetic	25	27	37	
VISIT 4 (WEEK 14), PREDOSE - Diabetic	2.2	4.3	16	
VISIT 4 (WEEK 14), PREDOSE - Non-diabetic	80	81	67	
VISIT 4 (WEEK 14), PREDOSE - Prediabetic	18	15	16	
VISIT 5 (WEEK 26), PREDOSE - Diabetic	4.5	2.2	13	
VISIT 5 (WEEK 26), PREDOSE - Non-diabetic	75	76	65	
VISIT 5 (WEEK 26), PREDOSE - Prediabetic	20	22	22	

Notes:

[95] - n=52 for Week 1 (baseline), n=45 for week 14 and n=44 for week 26.

[96] - n=52 for Week 1 (baseline), n=47 for week 14 and n=45 for week 26.

[97] - n=52 for Week 1 (baseline), n=49 for week 14 and n=46 for week 26.

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
----------------------------	--

Statistical analysis description:

The change from baseline in the proportion of diabetic and prediabetic patients after 14 weeks of treatment with EMP16-02 as compared to placebo was analyzed using Chi-square test without continuity correction.

The total number of subjects included in the analysis was 94 (the number 104 refers to Week 1).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0667
Method	Chi-squared

Statistical analysis title

EMP16-02 - 150/50 VS placebo - Week 14

Statistical analysis description:

The change from baseline in the proportion of diabetic and prediabetic patients after 14 weeks of treatment with EMP16-02 as compared to placebo was analyzed using Chi-square test without continuity correction.

The total number of subjects included in the analysis was 96 (the number 104 refers to Week 1).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1368
Method	Chi-squared

Statistical analysis title

EMP16-02 - 120/40 VS placebo - Week 26

Statistical analysis description:

The change from baseline in the proportion of diabetic and prediabetic patients after 26 weeks of treatment with EMP16-02 as compared to placebo was analyzed using Chi-square test without continuity correction.

The total number of subjects included in the analysis was 90 (the number 104 refers to Week 1).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3409
Method	Chi-squared

Statistical analysis title

EMP16-02 - 150/50 VS placebo - Week 26

Statistical analysis description:

The change from baseline in the proportion of diabetic and prediabetic patients after 26 weeks of treatment with EMP16-02 as compared to placebo was analyzed using Chi-square test without continuity correction.

The total number of subjects included in the analysis was 91 (the number 104 refers to Week 1).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1488
Method	Chi-squared

Secondary: Relative (%) change from baseline in systolic blood pressure after 14 weeks

End point title	Relative (%) change from baseline in systolic blood pressure after 14 weeks
-----------------	---

End point description:

Systolic and diastolic blood pressure were measured in supine position after 10 minutes of rest. This end-point reports the mean relative (%) change from baseline in systolic blood pressure after 14 weeks of treatment. The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood pressure was assessed at Visit 2 (Day 1, baseline) and at Visit 4 (Week 14).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	47	49	
Units: percent				
arithmetic mean (standard deviation)				
VISIT 4 (WEEK 14), PRE-DOSE	-1.9 (± 7.5)	-4.7 (± 9.5)	-1.4 (± 6.9)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
----------------------------	--

Statistical analysis description:

The relative (%) change from baseline in systolic and diastolic blood pressure, after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4224
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
Statistical analysis description:	
The relative (%) change from baseline in systolic and diastolic blood pressure, after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0273
Method	ANOVA

Secondary: Relative (%) change from baseline in systolic blood pressure after 26 weeks

End point title	Relative (%) change from baseline in systolic blood pressure after 26 weeks
-----------------	---

End point description:

Systolic and diastolic blood pressure were measured in supine position after 10 minutes of rest. This end-point reports the mean relative (%) change from baseline in systolic blood pressure after 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood pressure was assessed at Visit 2 (Day 1, baseline) and at Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	45	46	
Units: percent				
arithmetic mean (standard deviation)				
VISIT 5 (WEEK 26), PRE-DOSE	-1.7 (± 8.8)	-3.2 (± 9.2)	-1.1 (± 8.4)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
Statistical analysis description:	
The relative (%) change from baseline in systolic blood pressure after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 120/40 v Placebo

Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2631
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in systolic blood pressure after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	91
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0505
Method	ANOVA

Secondary: Absolute change from baseline in systolic blood pressure after 14 weeks

End point title	Absolute change from baseline in systolic blood pressure after 14 weeks
-----------------	---

End point description:

Systolic and diastolic blood pressure were measured in supine position after 10 minutes of rest. This end-point reports the mean absolute change from baseline in systolic blood pressure after 14 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood pressure was assessed at Visit 2 (Day 1, baseline) and at Visit 4 (Week 14).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	47	49	
Units: mmHg				
arithmetic mean (standard deviation)				
VISIT 4 (WEEK 14), PRE-DOSE	-2.6 (± 9.9)	-6.9 (± 13.4)	-2.2 (± 8.9)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
Statistical analysis description:	
The absolute change from baseline in diastolic blood pressure after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariates. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7327
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
Statistical analysis description:	
The absolute change from baseline in diastolic blood pressure after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariates. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.03
Method	ANCOVA

Secondary: Absolute change from baseline in systolic blood pressure after 26 weeks

End point title	Absolute change from baseline in systolic blood pressure after 26 weeks
-----------------	---

End point description:

Systolic and diastolic blood pressure were measured in supine position after 10 minutes of rest. This end-point reports the mean absolute change from baseline in systolic blood pressure after 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood pressure was assessed at Visit 2 (Day 1, baseline) and at Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	45	46	
Units: mmHg				
arithmetic mean (standard deviation)				
VISIT 5 (WEEK 26), PRE-DOSE	-2.7 (\pm 12.0)	-4.9 (\pm 13.6)	-1.8 (\pm 11.2)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
Statistical analysis description:	
The absolute change from baseline in systolic blood pressure after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariates. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5771
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
Statistical analysis description:	
The absolute change from baseline in systolic blood pressure after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariates. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	91
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1822
Method	ANCOVA

Secondary: Relative (%) change from baseline in diastolic blood pressure after 14 weeks

End point title	Relative (%) change from baseline in diastolic blood pressure after 14 weeks
-----------------	--

End point description:

Systolic and diastolic blood pressure were measured in supine position after 10 minutes of rest. This end-point reports the mean relative (%) change from baseline in diastolic blood pressure after 14 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
End point timeframe:	
Blood pressure was assessed at Visit 2 (Day 1, baseline) and at Visit 4 (Week 14).	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	47	49	
Units: percent				
arithmetic mean (standard deviation)				
VISIT 4 (WEEK 14), PRE-DOSE	-3.2 (± 8.2)	-3.3 (± 10.1)	0.6 (± 7.1)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
Statistical analysis description:	
The relative (%) change from baseline in diastolic blood pressure after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0215
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
Statistical analysis description:	
The relative (%) change from baseline in diastolic blood pressure after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0284
Method	ANOVA

Secondary: Relative (%) change from baseline in diastolic blood pressure after 26 weeks

End point title	Relative (%) change from baseline in diastolic blood pressure after 26 weeks
-----------------	--

End point description:

Systolic and diastolic blood pressure were measured in supine position after 10 minutes of rest. This end-point reports the mean relative (%) change from baseline in diastolic blood pressure after 26 weeks of treatment. 2

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood pressure was assessed at Visit 2 (Day 1, baseline) and at Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	45	46	
Units: percent				
arithmetic mean (standard deviation)				
VISIT 5 (WEEK 26), PRE-DOSE	-3.3 (± 8.1)	-2.8 (± 9.3)	-1.4 (± 8.7)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in diastolic blood pressure after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1509
Method	ANOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The relative (%) change from baseline in diastolic blood pressure after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANOVA with treatment as independent variable. Data underlying the ANOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	Placebo v EMP16-02 - 150/50
-------------------	-----------------------------

Number of subjects included in analysis	91
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.148
Method	ANOVA

Secondary: Absolute change from baseline in diastolic blood pressure after 14 weeks

End point title	Absolute change from baseline in diastolic blood pressure after 14 weeks
-----------------	--

End point description:

Systolic and diastolic blood pressure were measured in supine position after 10 minutes of rest. This end-point reports the mean absolute change from baseline in diastolic blood pressure after 14 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood pressure was assessed at Visit 2 (Day 1, baseline) and at Visit 4 (Week 14).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	47	49	
Units: mmHg				
arithmetic mean (standard deviation)				
VISIT 4 (WEEK 14), PRE-DOSE	-2.8 (± 7.0)	-3.3 (± 8.7)	0.2 (± 5.9)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
----------------------------	--

Statistical analysis description:

The absolute change from baseline in diastolic blood pressure after 14 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariates. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	94
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0542
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
Statistical analysis description:	
The absolute change from baseline in diastolic blood pressure after 14 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariates. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	96
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0221
Method	ANCOVA

Secondary: Absolute change from baseline in diastolic blood pressure after 26 weeks

End point title	Absolute change from baseline in diastolic blood pressure after 26 weeks
-----------------	--

End point description:

Systolic and diastolic blood pressure were measured in supine position after 10 minutes of rest. This end-point reports the mean absolute change from baseline in diastolic blood pressure after 26 weeks of treatment.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

Blood pressure was assessed at Visit 2 (Day 1, baseline) and at Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	45	46	
Units: mmHg				
arithmetic mean (standard deviation)				
VISIT 5 (WEEK 26), PRE-DOSE	-3.0 (± 7.0)	-3.0 (± 8.1)	-1.5 (± 7.3)	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
Statistical analysis description:	
The absolute change from baseline in diastolic blood pressure after 26 weeks of treatment with EMP16-120/40 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariates. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.	
Comparison groups	EMP16-02 - 120/40 v Placebo

Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3769
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in diastolic blood pressure after 26 weeks of treatment with EMP16-150/50 as compared to placebo was analyzed using ANCOVA with treatment as independent variable and body weight at baseline as covariates. Data underlying the ANCOVA has been imputed in case of missing values using Last Observation Carried Forward, LOCF.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	91
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.384
Method	ANCOVA

Secondary: Relative (%) change from baseline in quality of life after 26 weeks

End point title	Relative (%) change from baseline in quality of life after 26 weeks
-----------------	---

End point description:

The RAND-36 health questionnaire comprises 36 questions. The questionnaire taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perception. It also includes a single item that provides an indication of perceived change in health. A low score indicates poor health-related quality of life while a high score indicates good health-related quality of life.

This end-point reports the mean relative (%) change from baseline (Week 1, Day 1) in score mean for the 8 health concepts scales and for the additional "Health Transition Score" included in the questionnaire, at week 26. The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

The RAND-36 health questionnaire was filled in by the subjects at Visit 2 (Day 1, baseline) and at Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	42 ^[98]	41 ^[99]	47 ^[100]	
Units: percent				
arithmetic mean (standard deviation)				
1. Physical functioning Mean - Week 26	30.1 (± 110.8)	22.5 (± 38.2)	3.8 (± 17.7)	
2. Role functioning/Physical Mean - Week 26	19.4 (± 75.7)	35.4 (± 93.4)	6.9 (± 59.5)	

3. Pain (Bodily Pain) Mean -Week 26	5.6 (± 30.1)	23.4 (± 44.1)	2.8 (± 34.1)	
4. General health Mean -Week 26	12.6 (± 48.5)	10.8 (± 21.4)	-5.2 (± 19.8)	
5. Energy/fatigue (Vitality) Mean - Week 26	21.8 (± 114.2)	33.0 (± 102.3)	-3.0 (± 28.0)	
6. Social Functioning Mean - Week 26	5.0 (± 31.6)	28.2 (± 90.3)	0.7 (± 25.9)	
7. Role functioning/Emotional Mean - Week 26	-4.7 (± 47.0)	10.1 (± 76.6)	-13.7 (± 35.8)	
8. Emotional wellbeing (Mental) Mean - Week 26	-0.8 (± 29.0)	5.9 (± 34.4)	-4.9 (± 15.1)	
9. Health Transition score Mean - Week 26	41.3 (± 63.3)	48.4 (± 65.2)	13.0 (± 36.5)	

Notes:

[98] - n=42 for scale no 1, 3-6 & 8

n=39 for scale no 2 & 7

n=40 for scale no 9

[99] - n=41 for scale no 1

n=40 for scale no 2 & 9

n=41 for scale no 3-6 & 8

n=38 for scale no 7

[100] - n=47 for scale no 1, 3, 4, 6 & 8

n=46 for scale no 2, 5 & 9

n=45 for scale no 7

Statistical analyses

Statistical analysis title	Scale no 1 - EMP16-120/40 VS placebo
Statistical analysis description:	
The RAND-36 QoL questionnaire was analyzed in accordance with the manual. Between groups p-value (Wilcoxon) was compared between EMP16-02 and placebo. This statistical analysis regards scale no 1 of the RAND-36 questionnaire.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0131
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Scale no 1 - EMP16-150/50 VS placebo
Statistical analysis description:	
The RAND-36 QoL questionnaire was analyzed in accordance with the manual. Between groups p-value (Wilcoxon) was compared between EMP16-02 and placebo. This statistical analysis regards scale no 1 of the RAND-36 questionnaire.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	88
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0024
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Scale no 2 - EMP16-120/40 VS placebo
-----------------------------------	--------------------------------------

Statistical analysis description:

The RAND-36 QoL questionnaire was analyzed in accordance with the manual. Between groups p-value

(Wilcoxon) was compared between EMP16-02 and placebo. This statistical analysis regards scale no 2 of the RAND-36 questionnaire.

The total number of subjects included in the analysis was 85 (the number 89 refers to scale no 1).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2972
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Scale no 2 - EMP16-150/50 VS placebo
-----------------------------------	--------------------------------------

Statistical analysis description:

The RAND-36 QoL questionnaire was analyzed in accordance with the manual. Between groups p-value (Wilcoxon) was compared between EMP16-02 and placebo. This statistical analysis regards scale no 2 of the RAND-36 questionnaire.

The total number of subjects included in the analysis was 86 (the number 88 refers to scale no 1).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	88
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0923
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Scale no 3 - EMP16-120/40 VS placebo
-----------------------------------	--------------------------------------

Statistical analysis description:

The RAND-36 QoL questionnaire was analyzed in accordance with the manual. Between groups p-value (Wilcoxon) was compared between EMP16-02 and placebo. This statistical analysis regards scale no 3 of the RAND-36 questionnaire.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8938
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Scale no 3 - EMP16-150/50 VS placebo
-----------------------------------	--------------------------------------

Statistical analysis description:

The RAND-36 QoL questionnaire was analyzed in accordance with the manual. Between groups p-value (Wilcoxon) was compared between EMP16-02 and placebo. This statistical analysis regards scale no 3 of the RAND-36 questionnaire.

The total number of subjects included in the analysis was 88 (the number 89 refers to scale no 1).

Comparison groups	EMP16-02 - 150/50 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	88
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0278
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Scale no 4 - EMP16-120/40 VS placebo
-----------------------------------	--------------------------------------

Statistical analysis description:

The RAND-36 QoL questionnaire was analyzed in accordance with the manual. Between groups p-value (Wilcoxon) was compared between EMP16-02 and placebo. This statistical analysis regards scale no 4 of the RAND-36 questionnaire.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.018
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Scale no 4 - EMP16-150/50 VS placebo
-----------------------------------	--------------------------------------

Statistical analysis description:

The RAND-36 QoL questionnaire was analyzed in accordance with the manual. Between groups p-value (Wilcoxon) was compared between EMP16-02 and placebo. This statistical analysis regards scale no 4 of the RAND-36 questionnaire.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	88
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0006
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Scale no 5 - EMP16-120/40 VS placebo
-----------------------------------	--------------------------------------

Statistical analysis description:

The RAND-36 QoL questionnaire was analyzed in accordance with the manual. Between groups p-value (Wilcoxon) was compared between EMP16-02 and placebo. This statistical analysis regards scale no 5 of the RAND-36 questionnaire.

The total number of subjects included in the analysis was 88 (the number 89 refers to scale no 1).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4296
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Scale no 5 - EMP16-150/50 VS placebo
Statistical analysis description:	
The RAND-36 QoL questionnaire was analyzed in accordance with the manual. Between groups p-value (Wilcoxon) was compared between EMP16-02 and placebo. This statistical analysis regards scale no 5 of the RAND-36 questionnaire.	
The total number of subjects included in the analysis was 87 (the number 88 refers to scale no 1).	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	88
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0287
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Scale no 6 - EMP16-120/40 VS placebo
Statistical analysis description:	
The RAND-36 QoL questionnaire was analyzed in accordance with the manual. Between groups p-value (Wilcoxon) was compared between EMP16-02 and placebo. This statistical analysis regards scale no 6 of the RAND-36 questionnaire.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5647
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Scale no 6 - EMP16-150/50 VS placebo
Statistical analysis description:	
The RAND-36 QoL questionnaire was analyzed in accordance with the manual. Between groups p-value (Wilcoxon) was compared between EMP16-02 and placebo. This statistical analysis regards scale no 6 of the RAND-36 questionnaire.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	88
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0933
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Scale no 7 - EMP16-120/40 VS placebo
Statistical analysis description:	
The RAND-36 QoL questionnaire was analyzed in accordance with the manual. Between groups p-value (Wilcoxon) was compared between EMP16-02 and placebo. This statistical analysis regards scale no 7 of the RAND-36 questionnaire.	
The total number of subjects included in the analysis was 84 (the number 89 refers to scale no 1).	
Comparison groups	EMP16-02 - 120/40 v Placebo

Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3628
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Scale no 7 - EMP16-150/50 VS placebo
-----------------------------------	--------------------------------------

Statistical analysis description:

The RAND-36 QoL questionnaire was analyzed in accordance with the manual. Between groups p-value (Wilcoxon) was compared between EMP16-02 and placebo. This statistical analysis regards scale no 7 of the RAND-36 questionnaire.

The total number of subjects included in the analysis was 83 (the number 88 refers to scale no 1).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	88
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2153
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Scale no 8 - EMP16-120/40 VS placebo
-----------------------------------	--------------------------------------

Statistical analysis description:

The RAND-36 QoL questionnaire was analyzed in accordance with the manual. Between groups p-value (Wilcoxon) was compared between EMP16-02 and placebo. This statistical analysis regards scale no 8 of the RAND-36 questionnaire.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2484
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Scale no 8 - EMP16-150/50 VS placebo
-----------------------------------	--------------------------------------

Statistical analysis description:

The RAND-36 QoL questionnaire was analyzed in accordance with the manual. Between groups p-value (Wilcoxon) was compared between EMP16-02 and placebo. This statistical analysis regards scale no 8 of the RAND-36 questionnaire.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	88
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.039
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Scale no 9 - EMP16-120/40 VS placebo
Statistical analysis description:	
The RAND-36 QoL questionnaire was analyzed in accordance with the manual. Between groups p-value (Wilcoxon) was compared between EMP16-02 and placebo. This statistical analysis regards scale no 9 of the RAND-36 questionnaire.	
The total number of subjects included in the analysis was 86 (the number 89 refers to scale no 1).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	89
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0138
Method	Wilcoxon (Mann-Whitney)

Statistical analysis title	Scale no 9 - EMP16-150/50 VS placebo
Statistical analysis description:	
The RAND-36 QoL questionnaire was analyzed in accordance with the manual. Between groups p-value (Wilcoxon) was compared between EMP16-02 and placebo. This statistical analysis regards scale no 9 of the RAND-36 questionnaire.	
The total number of subjects included in the analysis was 87 (the number 88 refers to scale no 1).	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	88
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0057
Method	Wilcoxon (Mann-Whitney)

Secondary: Overall drop-out rate - Week 28	
End point title	Overall drop-out rate - Week 28
End point description:	
This end-point reports the cumulative overall drop-out rate (rate of early discontinuations) at the Safety follow-up Visit (Week 28). Subjects who missed one or several visits and who later re-entered the study were not considered drop-outs until they missed all remaining visits.	
The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.	
End point type	Secondary
End point timeframe:	
Collection of reasons for early discontinuations was done from Visit 1 Screening to Visit 6 (Week 28).	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	52	52	52	
Units: percent				
number (not applicable)				
Withdrawal overall - Week 28	15.4	13.5	11.5	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 28
Statistical analysis description:	
The overall drop-out rate following treatment with EMP16-02 as compared to placebo was analyzed using Chi-square test without continuity correction.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5656
Method	Chi-squared

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 28
Statistical analysis description:	
The overall drop-out rate following treatment with EMP16-02 as compared to placebo was analyzed using Chi-square test without continuity correction.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7668
Method	Chi-squared

Secondary: GI related drop-out rate - Week 28

End point title	GI related drop-out rate - Week 28
End point description:	
This end-point reports the cumulative gastrointestinal (GI) related drop-out rate (rate of early discontinuations) at the Safety follow-up Visit (Week 28). Subjects who missed one or several visits and who later re-entered the study were not considered drop-outs until they missed all remaining visits.	
The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.	
End point type	Secondary
End point timeframe:	
Collection of reasons for early discontinuations was done from Visit 1 Screening to Visit 6 (Week 28).	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	52	52	52	
Units: percent				
number (not applicable)				
GI related withdrawal - Week 28	7.7	9.6	0.0	

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 28
Statistical analysis description: The GI related drop-out rate following treatment with EMP16-120/40 as compared to placebo was analyzed using Chi-square test without continuity correction.	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0414
Method	Chi-squared

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 28
Statistical analysis description: The GI related drop-out rate following treatment with EMP16-150/50 as compared to placebo was analyzed using Chi-square test without continuity correction.	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0219
Method	Chi-squared

Secondary: Frequency, seriousness, severity and causality of adverse events (AEs)

End point title	Frequency, seriousness, severity and causality of adverse events (AEs)
------------------------	--

End point description:

This end-point reports frequency, seriousness, severity and causality of adverse events (AEs) and serious AEs (SAEs). The grading of the severity/intensity (grade 1 to grade 5) of AEs followed the common terminology criteria for AEs (CTCAE) v5.0. AEs were assessed as unlikely, possibly or probably related to the IMP.

GI symptoms were recorded using the Gastrointestinal symptom rating scale (GSRS) questionnaire. Only symptoms assessed by the Investigator as severe (either spontaneously reported or reported in

the GSRS questionnaire) were recorded as AEs unless the GI symptom led to an early withdrawal.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

AEs (including serious AEs [SAEs]) were collected from the start of IMP administration until the end-of-study visit of each part.

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	52	52	52	
Units: Number of subjects				
Any AE	32	39	30	
Any SAE	0	0	0	
Any AE leading to withdrawal	4	6	0	
Any AE leading to withdrawal of study drug	4	6	0	
Any AE leading to death	0	0	0	
Causality - Unlikely related	22	28	27	
Causality - Possibly related	7	9	6	
Causality - Probably related	13	12	2	
Severity - Mild	21	24	22	
Severity - Moderate	11	13	11	
Severity - Severe	14	12	3	
Severity - Life-threatening	0	0	0	
Severity - Death	0	0	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Clinically significant (CS) abnormal findings in vital signs

End point title	Clinically significant (CS) abnormal findings in vital signs
-----------------	--

End point description:

Systolic and diastolic blood pressure (BP) and pulse were measured in supine position after 10 minutes of rest. Vital signs were judged as normal, abnormal but not clinically significant (NCS) or abnormal and clinically significant (CS). Overall, there were no clinically relevant changes in mean systolic and diastolic BP between baseline and week 7, 14 and 26, respectively, in any treatment group. Similarly, there were no clinically relevant changes in mean pulse between the corresponding time points in any treatment group.

This end-point reports CS abnormal findings in systolic & diastolic BP and pulse.

End point type	Secondary
----------------	-----------

End point timeframe:

Vital signs were assessed at Visit 1 Screening, Visit 2 (Baseline), Visit 3 (Week 7), Visit 4 (Week 14), Visit 5 (Week 26) and Visit 6 (Week 28).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	52	52	52	
Units: Number of abnormal CS findings				
CS abnormal findings in pulse	0	0	0	
CS abnormal findings in blood pressure	0	0	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Abnormal Clinically Significant findings in ECG

End point title	Abnormal Clinically Significant findings in ECG
-----------------	---

End point description:

Single 12-lead ECGs were recorded in supine position after 10 minutes of rest using an ECG machine. Safety ECGs were reviewed and interpreted on-site by the Investigator. Any abnormalities were specified and documented in the eCRF as clinically significant (CS) or not clinically significant (NCS).

All ECGs were interpreted as normal or abnormal NCS by the Investigator at screening, week 28 or at early discontinuation end-of-study visits. There were no clinically relevant changes from baseline and no obvious differences between the treatment groups in terms of overall ECG evaluations and individual ECG parameters.

One patient in the EMP16-120/40 group reported intermittent palpitations assessed as mild and unlikely related to treatment with the IMP by the Investigator. The occurrences started almost 3 months after the first dose and lasted over a period of 26 days. The ECG of the patient was interpreted as normal both at screening and at week 28.

End point type	Secondary
----------------	-----------

End point timeframe:

ECG assessment was performed at Visit 1 Screening and at Visit 6 Safety follow-up (Week 28), or at early discontinuation end-of-study visits.

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	52 ^[101]	52 ^[102]	52 ^[103]	
Units: Number of abnormal CS findings				
Abnormal CS ECG findings - Screening	0	0	0	
Abnormal CS ECG findings - Week 28	0	0	0	
Abnormal CS ECG findings - End of Study	0	0	0	

Notes:

[101] - n=52 for Screening Visit, n=44 for Week 28 and n=4 for End of study Visit

[102] - n=52 for Screening Visit, n=45 for Week 28 and n=6 for End of study Visit

[103] - n=52 for Screening Visit, n=45 for Week 28 and n=3 for End of study Visit

Statistical analyses

No statistical analyses for this end point

Secondary: Abnormal Clinically Significant findings in Clinical Chemistry

End point title	Abnormal Clinically Significant findings in Clinical Chemistry
-----------------	--

End point description:

Blood samples for analysis of clinical chemistry parameters were collected through venipuncture and analyzed by routine analytical methods. The following parameters were analyzed: ALT, Albumin, ALP, AST, Bilirubin (total and conjugated), Calcium, Creatinine, GGT, Glucose, Hb1Ac, Phosphate, Potassium, Sodium and Urea.

Parameter values were assessed as normal, abnormal but not clinically significant (NCS) or abnormal and clinically significant (CS) by the Investigator.

There were no clinically relevant changes from baseline in mean clinical chemistry parameters over time and no clinically relevant differences in any laboratory parameter between any of the active treatment groups or the placebo group at any time point as assessed by the Investigator. Individual CS abnormalities were found for five patients, as reported in this end-point.

End point type	Secondary
----------------	-----------

End point timeframe:

Clinical chemistry laboratory parameters were assessed at pre-specified visits from Visit 1 Screening to Visit 6 (Week 28). In addition, for one subject an extra visit in between week 14 and week 26 was scheduled for assessment of AST.

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44 ^[104]	45 ^[105]	46 ^[106]	
Units: Number of subjects				
Abnormal CS finding - Week 26	1	1	1	
Abnormal CS finding - Week 28	1	0	0	
Abnormal CS finding - Extra Visit 1 subject only	0	1	0	

Notes:

[104] - At Week 28, 44 subjects remained in the study. For each specific analysis n may however vary.

[105] - At Week 28, 45 subjects remained in the study. For each specific analysis n may however vary.

[106] - At Week 28, 46 subjects remained in the study. For each specific analysis n may however vary.

Statistical analyses

No statistical analyses for this end point

Secondary: Abnormal CS findings in hematology, coagulation and urinalysis

End point title	Abnormal CS findings in hematology, coagulation and urinalysis
-----------------	--

End point description:

Blood samples for analysis of hematology and coagulation parameters were collected through venipuncture and analyzed by routine analytical methods. Urine analysis was performed at each research clinic using dip sticks.

Parameter values were assessed as normal, abnormal but not clinically significant (NCS) or abnormal and clinically significant (CS) by the Investigator.

There were no clinically relevant changes from baseline in mean hematology, coagulation or urinalysis parameters over time and no clinically relevant differences in any laboratory parameter between any of the active treatment groups or the placebo group at any time point as assessed by the Investigator. All

hematology, coagulation and urinalysis values were assessed as normal or abnormal NCS.

This end-point reports the number of abnormal CS findings for hematology, coagulation or urinalysis parameters (none).

End point type	Secondary
End point timeframe:	
Hematology, coagulation and urinalysis parameters were assessed at pre-specified visits from Visit 1 Screening to Visit 6 (Week 28).	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44 ^[107]	45 ^[108]	46 ^[109]	
Units: Number of abnormal CS findings				
Abnormal CS findings	0	0	0	

Notes:

[107] - At Week 28, 44 subjects remained in the study. For each specific analysis n may however vary.

[108] - At Week 28, 45 subjects remained in the study. For each specific analysis n may however vary.

[109] - At Week 28, 46 subjects remained in the study. For each specific analysis n may however vary.

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment compliance

End point title	Treatment compliance
End point description:	
This end-point reports the IMP compliance (%), calculated as follows:	
$\text{compliance} = (\text{number of delivered capsules} - \text{number of returned capsules}) / \text{number of delivered capsules}$	
The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.	
End point type	Secondary
End point timeframe:	
Compliance was calculated for subjects who had completed the whole treatment period.	

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	46	49	
Units: percent				
arithmetic mean (standard deviation)	95 (± 10)	96 (± 5)	93 (± 10)	

Statistical analyses

Secondary: Absolute change from baseline in GSRS total score

End point title	Absolute change from baseline in GSRS total score
-----------------	---

End point description:

The gastrointestinal symptom rating scale (GSRS) questionnaire contains 15 items in 5 dimensions (diarrhea syndrome, indigestion syndrome, constipation syndrome, abdominal pain syndrome and reflux syndrome) and uses a 7-graded Likert scale where 1 represents the most positive option and 7 the most negative one (no discomfort at all, minor discomfort, mild discomfort, moderate discomfort, moderately severe discomfort, severe discomfort, very severe discomfort).

This end-point reports the mean absolute change from baseline in GSRS total score at end of Week 2, end of Week 4, Week 7, End of Week 8, Week 14 and Week 26.

The data presented for this end-point was based on the full analysis set (FAS), i.e. all subjects who were randomised and received at least one dose of the IMP and who had at least one post-baseline assessment of efficacy data.

End point type	Secondary
----------------	-----------

End point timeframe:

The GSRS questionnaire was answered by the subjects at Visit 2 (Day 1, Baseline), end of Week 2 and 4, Visit 3 (Week 7), end of Week 8, Visit 4 (Week 14) and Visit 5 (Week 26).

End point values	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	52 ^[110]	49 ^[111]	51 ^[112]	
Units: number				
arithmetic mean (standard deviation)				
End of Week 2	0.6 (± 0.7)	0.7 (± 0.6)	0.3 (± 0.6)	
End of Week 4	0.7 (± 0.7)	0.7 (± 0.5)	0.3 (± 0.5)	
Week 7	0.9 (± 0.7)	0.9 (± 0.7)	0.3 (± 0.5)	
End of Week 8	0.8 (± 0.8)	0.9 (± 0.7)	0.4 (± 0.5)	
Week 14	0.8 (± 0.9)	1.0 (± 0.7)	0.3 (± 0.5)	
Week 26	0.6 (± 0.8)	0.7 (± 0.7)	0.1 (± 0.4)	

Notes:

[110] - n=52 for Week 2

n=49 for Week 4

n=45 for Week 7

n=48 for Week 8

n=42 for Week 14 & 26

[111] - n=49 for Week 2, 4 & 8

n=41 for Week 7

n=45 for Week 14

n=42 for Week 26

[112] - n=51 for Week 2

n=52 for Week 4

n=45 for Week 7

n=49 for Week 8

n=48 for Week 14

n=47 for W 26

Statistical analyses

Statistical analysis title	EMP16-02 - 120/40 VS placebo - End of Week 2
----------------------------	--

Statistical analysis description:

The absolute change from baseline in total score were analyzed using ANCOVA, with treatment as

independent variable and body weight at baseline as covariate.

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	103
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0271
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - End of Week 2
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in total score were analyzed using ANCOVA, with treatment as independent variable and body weight at baseline as covariate.

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0033
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - End of Week 4
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in total score were analyzed using ANCOVA, with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 101 (the number 103 refers to End of Week 2).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	103
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0004
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - End of Week 4
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in total score were analyzed using ANCOVA, with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 101 (the number 100 refers to End of Week 2).

Comparison groups	EMP16-02 - 150/50 v Placebo
-------------------	-----------------------------

Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0005
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 7
-----------------------------------	---------------------------------------

Statistical analysis description:

The absolute change from baseline in total score were analyzed using ANCOVA, with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 90 (the number 103 refers to End of Week 2).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	103
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 7
-----------------------------------	---------------------------------------

Statistical analysis description:

The absolute change from baseline in total score were analyzed using ANCOVA, with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 86 (the number 100 refers to End of Week 2).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0001
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - End of Week 8
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in total score were analyzed using ANCOVA, with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 97 (the number 103 refers to End of Week 2).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	103
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.005
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - End of Week 8
Statistical analysis description:	
The absolute change from baseline in total score were analyzed using ANCOVA, with treatment as independent variable and body weight at baseline as covariate.	
The total number of subjects included in the analysis was 98 (the number 100 refers to End of Week 2).	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0008
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 14
Statistical analysis description:	
The absolute change from baseline in total score were analyzed using ANCOVA, with treatment as independent variable and body weight at baseline as covariate.	
The total number of subjects included in the analysis was 90 (the number 103 refers to End of Week 2).	
Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	103
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0015
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 14
Statistical analysis description:	
The absolute change from baseline in total score were analyzed using ANCOVA, with treatment as independent variable and body weight at baseline as covariate.	
The total number of subjects included in the analysis was 93 (the number 100 refers to End of Week 2).	
Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA

Statistical analysis title	EMP16-02 - 120/40 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in total score were analyzed using ANCOVA, with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 89 (the number 103 refers to End of Week 2).

Comparison groups	EMP16-02 - 120/40 v Placebo
Number of subjects included in analysis	103
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0017
Method	ANCOVA

Statistical analysis title	EMP16-02 - 150/50 VS placebo - Week 26
-----------------------------------	--

Statistical analysis description:

The absolute change from baseline in total score were analyzed using ANCOVA, with treatment as independent variable and body weight at baseline as covariate.

The total number of subjects included in the analysis was 89 (the number 100 refers to End of Week 2).

Comparison groups	EMP16-02 - 150/50 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	ANCOVA

Adverse events

Adverse events information

Timeframe for reporting adverse events:

AEs (including serious AEs [SAEs]) were collected from the start of IMP administration until the end-of-study visit of each part.

Adverse event reporting additional description:

The grading of the severity of AEs followed the common terminology criteria for AEs (CTCAE) v5.0. AEs were assessed as unlikely, possibly or probably related to the IMP. GI symptoms were recorded using the GSRS questionnaire. Only symptoms assessed by the Investigator as severe were recorded as AEs unless the GI symptom led to an early withdrawal.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.0
--------------------	------

Reporting groups

Reporting group title	EMP16-02 - 120/40
-----------------------	-------------------

Reporting group description:

In this study patients were randomized in a 1:1:1 ratio to either of 2 doses of EMP16-02 or placebo. This arm (n=52) represents the group of patients who were randomized to receive EMP16-02 -120/40 (120 mg orlistat/40 mg acarbose).

Reporting group title	EMP16-02 - 150/50
-----------------------	-------------------

Reporting group description:

In this study patients were randomized in a 1:1:1 ratio to either of 2 doses of EMP16-02 or placebo. This arm (n=52) represents the group of patients who were randomized to receive EMP16-02-150/50 (150 mg orlistat/50 mg acarbose).

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

In this study patients were randomized in a 1:1:1 ratio to either of 2 doses of EMP16-02 or placebo. This arm (n=52) represents the group of patients who were randomized to receive placebo.

Serious adverse events	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 52 (0.00%)	0 / 52 (0.00%)	0 / 52 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	EMP16-02 - 120/40	EMP16-02 - 150/50	Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	32 / 52 (61.54%)	39 / 52 (75.00%)	30 / 52 (57.69%)
Vascular disorders			

Hypertension subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0
Surgical and medical procedures Knee operation subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0
Skin neoplasm excision subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0
Toe operation subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0
General disorders and administration site conditions Chest pain subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0
Condition aggravated subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	3 / 52 (5.77%) 3	0 / 52 (0.00%) 0
Inflammation subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0
Sensation of foreign body subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0	1 / 52 (1.92%) 1
Reproductive system and breast disorders Haematospermia subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0	1 / 52 (1.92%) 1

Menometrorrhagia subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0
Ovarian cyst subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0	1 / 52 (1.92%) 1
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	2 / 52 (3.85%) 2	0 / 52 (0.00%) 0
Psychiatric disorders Depression subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0	2 / 52 (3.85%) 2
Hallucination, auditory subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0	1 / 52 (1.92%) 1
Major depression subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0	1 / 52 (1.92%) 1
Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0
Injury, poisoning and procedural complications			

Road traffic accident subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0	1 / 52 (1.92%) 1
Thermal burn subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0
Nervous system disorders Amnesia subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0	1 / 52 (1.92%) 1
Dizziness subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	4 / 52 (7.69%) 5	2 / 52 (3.85%) 2	3 / 52 (5.77%) 4
Paresthesia subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0
Sciatica subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0	1 / 52 (1.92%) 1
Ear and labyrinth disorders Otolithiasis subjects affected / exposed occurrences (all)	1 / 52 (1.92%) 1	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0	1 / 52 (1.92%) 1
Vertigo positional subjects affected / exposed occurrences (all)	0 / 52 (0.00%) 0	0 / 52 (0.00%) 0	1 / 52 (1.92%) 1
Eye disorders			

Blepharitis			
subjects affected / exposed	0 / 52 (0.00%)	0 / 52 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1
Retinal detachment			
subjects affected / exposed	1 / 52 (1.92%)	0 / 52 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 52 (1.92%)	1 / 52 (1.92%)	0 / 52 (0.00%)
occurrences (all)	1	1	0
Abdominal distension			
subjects affected / exposed	4 / 52 (7.69%)	1 / 52 (1.92%)	0 / 52 (0.00%)
occurrences (all)	4	1	0
Abdominal pain			
subjects affected / exposed	2 / 52 (3.85%)	0 / 52 (0.00%)	0 / 52 (0.00%)
occurrences (all)	2	0	0
Abdominal pain upper			
subjects affected / exposed	1 / 52 (1.92%)	1 / 52 (1.92%)	0 / 52 (0.00%)
occurrences (all)	1	1	0
Anal incontinence			
subjects affected / exposed	0 / 52 (0.00%)	1 / 52 (1.92%)	0 / 52 (0.00%)
occurrences (all)	0	1	0
Constipation			
subjects affected / exposed	0 / 52 (0.00%)	0 / 52 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1
defecation urgency			
subjects affected / exposed	1 / 52 (1.92%)	2 / 52 (3.85%)	1 / 52 (1.92%)
occurrences (all)	1	2	1
Diarrhoea			
subjects affected / exposed	8 / 52 (15.38%)	8 / 52 (15.38%)	0 / 52 (0.00%)
occurrences (all)	9	9	0
Dyspepsia			
subjects affected / exposed	1 / 52 (1.92%)	0 / 52 (0.00%)	1 / 52 (1.92%)
occurrences (all)	1	0	1
Encopresis			

subjects affected / exposed	1 / 52 (1.92%)	0 / 52 (0.00%)	0 / 52 (0.00%)
occurrences (all)	2	0	0
Flatulence			
subjects affected / exposed	4 / 52 (7.69%)	3 / 52 (5.77%)	1 / 52 (1.92%)
occurrences (all)	4	4	1
Food poisoning			
subjects affected / exposed	0 / 52 (0.00%)	0 / 52 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1
Gastrointestinal motility disorder			
subjects affected / exposed	1 / 52 (1.92%)	0 / 52 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Gastroesophageal reflux disease			
subjects affected / exposed	1 / 52 (1.92%)	0 / 52 (0.00%)	1 / 52 (1.92%)
occurrences (all)	1	0	1
Lip swelling			
subjects affected / exposed	0 / 52 (0.00%)	0 / 52 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1
Mucous stools			
subjects affected / exposed	0 / 52 (0.00%)	1 / 52 (1.92%)	0 / 52 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	0 / 52 (0.00%)	1 / 52 (1.92%)	0 / 52 (0.00%)
occurrences (all)	0	1	0
Toothache			
subjects affected / exposed	0 / 52 (0.00%)	0 / 52 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	1 / 52 (1.92%)	0 / 52 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Eczema			
subjects affected / exposed	1 / 52 (1.92%)	1 / 52 (1.92%)	0 / 52 (0.00%)
occurrences (all)	1	1	0
Hyperhidrosis			
subjects affected / exposed	0 / 52 (0.00%)	1 / 52 (1.92%)	0 / 52 (0.00%)
occurrences (all)	0	1	0

Petechiae			
subjects affected / exposed	1 / 52 (1.92%)	0 / 52 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Pruritus			
subjects affected / exposed	0 / 52 (0.00%)	1 / 52 (1.92%)	1 / 52 (1.92%)
occurrences (all)	0	1	1
Rash			
subjects affected / exposed	0 / 52 (0.00%)	0 / 52 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1
Urticaria			
subjects affected / exposed	1 / 52 (1.92%)	0 / 52 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			
Hypertonic bladder			
subjects affected / exposed	0 / 52 (0.00%)	0 / 52 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 52 (0.00%)	2 / 52 (3.85%)	1 / 52 (1.92%)
occurrences (all)	0	3	1
Back pain			
subjects affected / exposed	1 / 52 (1.92%)	0 / 52 (0.00%)	1 / 52 (1.92%)
occurrences (all)	1	0	1
Joint swelling			
subjects affected / exposed	0 / 52 (0.00%)	0 / 52 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1
Musculoskeletal pain			
subjects affected / exposed	1 / 52 (1.92%)	0 / 52 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Myalgia			
subjects affected / exposed	0 / 52 (0.00%)	0 / 52 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1
Myositis			
subjects affected / exposed	0 / 52 (0.00%)	1 / 52 (1.92%)	0 / 52 (0.00%)
occurrences (all)	0	1	0
Neck pain			

subjects affected / exposed	1 / 52 (1.92%)	0 / 52 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Pain in extremity			
subjects affected / exposed	0 / 52 (0.00%)	1 / 52 (1.92%)	0 / 52 (0.00%)
occurrences (all)	0	1	0
Plantar fasciitis			
subjects affected / exposed	1 / 52 (1.92%)	1 / 52 (1.92%)	0 / 52 (0.00%)
occurrences (all)	1	1	0
Synovial cyst			
subjects affected / exposed	1 / 52 (1.92%)	0 / 52 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Tendonitis			
subjects affected / exposed	0 / 52 (0.00%)	1 / 52 (1.92%)	0 / 52 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 52 (0.00%)	6 / 52 (11.54%)	2 / 52 (3.85%)
occurrences (all)	0	6	2
Ear infection			
subjects affected / exposed	1 / 52 (1.92%)	0 / 52 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Fungal skin infection			
subjects affected / exposed	1 / 52 (1.92%)	0 / 52 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis			
subjects affected / exposed	1 / 52 (1.92%)	0 / 52 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal infection			
subjects affected / exposed	0 / 52 (0.00%)	0 / 52 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1
Herpes zoster			
subjects affected / exposed	0 / 52 (0.00%)	0 / 52 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1
Influenza			
subjects affected / exposed	0 / 52 (0.00%)	0 / 52 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1

Nasopharyngitis			
subjects affected / exposed	4 / 52 (7.69%)	10 / 52 (19.23%)	13 / 52 (25.00%)
occurrences (all)	4	10	15
Otitis media			
subjects affected / exposed	0 / 52 (0.00%)	1 / 52 (1.92%)	0 / 52 (0.00%)
occurrences (all)	0	1	0
Rhinitis			
subjects affected / exposed	1 / 52 (1.92%)	0 / 52 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 52 (0.00%)	0 / 52 (0.00%)	2 / 52 (3.85%)
occurrences (all)	0	0	2
Urinary tract infection			
subjects affected / exposed	0 / 52 (0.00%)	1 / 52 (1.92%)	0 / 52 (0.00%)
occurrences (all)	0	1	0
Metabolism and nutrition disorders			
Diabetes mellitus			
subjects affected / exposed	0 / 52 (0.00%)	1 / 52 (1.92%)	1 / 52 (1.92%)
occurrences (all)	0	1	1
Food craving			
subjects affected / exposed	1 / 52 (1.92%)	0 / 52 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Gout			
subjects affected / exposed	1 / 52 (1.92%)	0 / 52 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 52 (0.00%)	0 / 52 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1
Increased appetite			
subjects affected / exposed	1 / 52 (1.92%)	1 / 52 (1.92%)	0 / 52 (0.00%)
occurrences (all)	1	1	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 November 2020	Addition of a voluntary, long-term follow-up visit 6 months after completion of the 26-weeks treatment period with EMP16 02 for assessment of weight, HbA1c and blood pressure. Addition of trough plasma concentration measurements of acarbose at steady state. Administrative changes, clarifications and corrections of typos.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported